<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1432" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1432/" /><meta name="ncbi_pagename" content="X-Linked Myotubular Myopathy - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>X-Linked Myotubular Myopathy - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="X-Linked Myotubular Myopathy" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2018/08/23" /><meta name="citation_author" content="James J Dowling" /><meta name="citation_author" content="Michael W Lawlor" /><meta name="citation_author" content="Soma Das" /><meta name="citation_pmid" content="20301605" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1432/" /><meta name="citation_keywords" content="Myotubular Myopathy (MTM)" /><meta name="citation_keywords" content="XLCNM" /><meta name="citation_keywords" content="X-Linked Centronuclear Myopathy" /><meta name="citation_keywords" content="XLMTM" /><meta name="citation_keywords" content="Myotubular Myopathy (MTM)" /><meta name="citation_keywords" content="XLCNM" /><meta name="citation_keywords" content="X-Linked Centronuclear Myopathy" /><meta name="citation_keywords" content="XLMTM" /><meta name="citation_keywords" content="Myotubularin" /><meta name="citation_keywords" content="MTM1" /><meta name="citation_keywords" content="X-Linked Myotubular Myopathy" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="X-Linked Myotubular Myopathy" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="James J Dowling" /><meta name="DC.Contributor" content="Michael W Lawlor" /><meta name="DC.Contributor" content="Soma Das" /><meta name="DC.Date" content="2018/08/23" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1432/" /><meta name="description" content="X-linked myotubular myopathy (X-MTM), also known as myotubular myopathy (MTM), is characterized by muscle weakness that ranges from severe to mild." /><meta name="og:title" content="X-Linked Myotubular Myopathy" /><meta name="og:type" content="book" /><meta name="og:description" content="X-linked myotubular myopathy (X-MTM), also known as myotubular myopathy (MTM), is characterized by muscle weakness that ranges from severe to mild." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1432/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/mtm/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1432/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8A40B7E04091C100000000070002B0.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1432_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1432_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/retinoschisis/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/opitz/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1432_"><span class="title" itemprop="name">X-Linked Myotubular Myopathy</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: Myotubular Myopathy (MTM), XLCNM, X-Linked Centronuclear Myopathy, XLMTM</div><p class="contrib-group"><span itemprop="author">James J Dowling</span>, MD, PhD, <span itemprop="author">Michael W Lawlor</span>, MD, PhD, and <span itemprop="author">Soma Das</span>, PhD.</p><a data-jig="ncbitoggler" href="#__NBK1432_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1432_ai__"><div class="contrib half_rhythm"><span itemprop="author">James J Dowling</span>, MD, PhD<div class="affiliation small">Division of Neurology<br />Program for Genetics and Genome Biology<br />Hospital for Sick Children<br />Toronto, Ontario, Canada<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ac.sdikkcis@gnilwod.semaj" class="oemail">ac.sdikkcis@gnilwod.semaj</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Michael W Lawlor</span>, MD, PhD<div class="affiliation small">Department of Pathology and Laboratory Medicine and Neuroscience Research Center<br />Medical College of Wisconsin<br />Milwaukee, Wisconsin<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.wcm@rolwalm" class="oemail">ude.wcm@rolwalm</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Soma Das</span>, PhD<div class="affiliation small">Department of Human Genetics<br />University of Chicago<br />Chicago, Illinois<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.ogacihcu.sciteneg@sads" class="oemail">ude.ogacihcu.sciteneg@sads</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">February 25, 2002</span>; Last Update: <span itemprop="dateModified">August 23, 2018</span>.</p><p><em>Estimated reading time: 33 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="mtm.Summary" itemprop="description"><h2 id="_mtm_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p><a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> myotubular myopathy (X-MTM), also known as myotubular myopathy (MTM), is characterized by muscle weakness that ranges from severe to mild.</p><p>Approximately 80% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males present with severe (classic) X-MTM characterized by polyhydramnios, decreased fetal movement, and neonatal weakness, hypotonia, and respiratory failure. Motor milestones are significantly delayed and most individuals fail to achieve independent ambulation. Weakness is profound and often involves facial and extraocular muscles. Respiratory failure is nearly uniform, with most individuals requiring 24-hour ventilatory assistance. It is estimated that at least 25% of boys with severe X-MTM die in the first year of life, and those who survive rarely live into adulthood.</p><p>Males with mild or moderate X-MTM (~20%) achieve motor milestones more quickly than males with the severe form; many ambulate independently, and may live into adulthood. Most require gastrostomy tubes and/or ventilator support. In all subtypes of X-MTM, the muscle disease is not obviously progressive. Female carriers of X-MTM are generally asymptomatic, although manifesting heterozygotes are increasingly being identified. In <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> females, symptoms range from severe, generalized weakness presenting in childhood, with infantile onset similar to affected male patients, to mild (often asymmetric) weakness manifesting in adulthood. Affected adult females may experience progressive respiratory decline and ultimately require ventilatory support.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of X-MTM is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with suggestive clinical findings and identification of a <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>MTM1</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations</i>: Treatment is supportive. Management optimally involves a team of specialists with expertise in the long-term care of children and/or adults with neuromuscular disorders, often including a pulmonologist, neurologist, physical therapist and/or rehabilitation medicine specialist, and clinical geneticist. Tracheostomy, G-tube feeding, and assistive communication devices are often required. Ophthalmologists, orthopedists, and orthodontists should address specific medical complications related to the underlying myopathy.</p><p><i>Surveillance</i>: Annual pulmonary assessment; polysomnography every one to three years; routine examination for scoliosis; annual ophthalmologic examinations to evaluate for ophthalmoplegia, ptosis, and myopia; routine assessment for dental malocclusion.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>X-MTM is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> manner. The risk to sibs of a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> depends on the <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status of the mother. If the mother is a carrier, each sib has a 50% chance of inheriting the <i>MTM1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. Males who inherit the variant will be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>; females who inherit the variant will be carriers and will generally not be affected. To date, there are no reported males with incomplete <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>. In <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases (i.e., a single occurrence in a family), there is a probability of 80%-90% that a woman is a carrier if her son has a confirmed <i>MTM1</i> pathogenic variant. Thus, about 10%-20% of males who represent simplex cases have a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variant in <i>MTM1</i> and a mother who is not a carrier. Germline <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a> has been reported. Carrier testing of at-risk female relatives and prenatal testing for a pregnancy at risk are possible if the <i>MTM1</i> pathogenic variant has been identified in an affected male relative.</p></div></div><div id="mtm.Diagnosis"><h2 id="_mtm_Diagnosis_">Diagnosis</h2><div id="mtm.Suggestive_Findings"><h3>Suggestive Findings</h3><p>The diagnosis of <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> myotubular myopathy (X-MTM), also known as myotubular myopathy (MTM), <b>should be suspected in any male</b> with the following clinical and histopathologic features.</p><p><b>Clinical features</b></p><ul><li class="half_rhythm"><div>Neonatal hypotonia</div></li><li class="half_rhythm"><div>Neonatal respiratory failure</div></li><li class="half_rhythm"><div>Significant and diffuse muscle weakness</div></li><li class="half_rhythm"><div>Diminished muscle bulk</div></li><li class="half_rhythm"><div>A family history suggestive of <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> inheritance</div></li><li class="half_rhythm"><div>Length and head circumference &#x0003e;90th centile</div></li><li class="half_rhythm"><div>Cryptorchidism</div></li><li class="half_rhythm"><div>Long fingers and toes</div></li><li class="half_rhythm"><div>Involvement of the extraocular muscles (i.e., ophthalmoparesis)</div></li></ul><p><b>Histopathologic</b>
<b>features</b> on muscle biopsy [<a class="bk_pop" href="#mtm.REF.lawlor.2016.102">Lawlor et al 2016</a>]</p><ul><li class="half_rhythm"><div>Numerous small, rounded myofibers with internally located nuclei that are present at (or very near) the center of a myofiber. The nucleus often appears very large in comparison to the small fiber size.</div></li><li class="half_rhythm"><div>Aberrant accumulation of centrally located staining with oxidative stains (SDH and NADH) and glycogen stains (PAS), often in conjunction with a halo-like area of subsarcolemmal clearing on these stains</div></li><li class="half_rhythm"><div>Small, predominant type I fibers</div></li><li class="half_rhythm"><div>Necklace fibers on hematoxylin-eosin stained sections and with succinate dehydrogenase staining; present in some individuals with <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> late-onset X-MTM as a basophilic ring-like deposit that follows the contour of the myofiber and aligns with internal myonuclei</div></li></ul><p>The diagnosis of X-MTM <b>should be considered in females</b> with the following clinical and histopathologic features:</p><ul><li class="half_rhythm"><div>Mild to moderate extremity weakness in a limb girdle pattern, often with prominent asymmetry</div></li><li class="half_rhythm"><div>Asymmetric muscle growth</div></li><li class="half_rhythm"><div>Facial weakness, ptosis, and ophthalmoparesis</div></li><li class="half_rhythm"><div>A family history suggestive of <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> inheritance (<a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> females may not have a family history of X-MTM)</div></li><li class="half_rhythm"><div>Necklace fibers on muscle biopsy, or features of typical centronuclear myopathy</div></li></ul></div><div id="mtm.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p><b>Male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The diagnosis of X-MTM <b>is established</b> in a male proband with suggestive clinical findings and identification of a <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>MTM1</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1432/table/mtm.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figmtmTmoleculargenetictestingusedin" rid-ob="figobmtmTmoleculargenetictestingusedin">Table 1</a>).</p><p><b>Female <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The diagnosis of X-MTM <b>is usually established</b> in a female proband with suggestive clinical findings and identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>MTM1</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1432/table/mtm.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figmtmTmoleculargenetictestingusedin" rid-ob="figobmtmTmoleculargenetictestingusedin">Table 1</a>).</p><p>Molecular genetic testing approaches can include a combination of <b><a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted testing</b> (<a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a>, single-gene testing) and <b>comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (<a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a>, <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a>, <a class="def" href="/books/n/gene/glossary/def-item/exome-array/">exome array</a>) depending on the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</p><p>Gene-targeted testing requires that the clinician determine which <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>(s) are likely involved, whereas <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing does not. Because the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of X-MTM is broad, individuals with the distinctive findings described in <a href="#mtm.Suggestive_Findings">Suggestive Findings</a> are likely to be diagnosed using gene-targeted testing (see <a href="#mtm.Option_1">Option 1</a>), whereas those with a phenotype indistinguishable from many other inherited disorders with myopathy are more likely to be diagnosed using genomic testing (see <a href="#mtm.Option_2">Option 2</a>).</p><div id="mtm.Option_1"><h4>Option 1</h4><p>When the phenotypic and laboratory findings suggest the diagnosis of X-MTM, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> approaches can include a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> or <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>MTM1</i> and other genes of interest (see <a href="#mtm.Differential_Diagnosis">Differential Diagnosis</a>) is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests. For this disorder a multigene panel that also includes deletion/duplication analysis is recommended (see <a class="figpopup" href="/books/NBK1432/table/mtm.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figmtmTmoleculargenetictestingusedin" rid-ob="figobmtmTmoleculargenetictestingusedin">Table 1</a>).</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Rarely, single-gene testing can be considered under the appropriate circumstances. These include: (a) a male child with weakness and a positive family history of X-MTM; or (b) a severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male infant with physical features consistent with X-MTM, including diffuse weakness, ophthalmoparesis, and length and head circumference &#x0003e;90th centile. Sequence analysis of <i>MTM1</i> is performed first and followed by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> if no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found.</div></li></ul></div><div id="mtm.Option_2"><h4>Option 2</h4><p>When the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> is indistinguishable from many other inherited disorders characterized by myopathy, <b>comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (which does not require the clinician to determine which <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>[s] are likely involved) is the best option. <b>Exome sequencing</b> is most commonly used; <b><a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a></b> is also possible.</p><p>If <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> is not diagnostic, <b><a class="def" href="/books/n/gene/glossary/def-item/exome-array/">exome array</a></b> (when clinically available) may be considered to detect (multi)<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications that cannot be detected by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>.</p><p>For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</p><div id="mtm.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in X-Linked Myotubular Myopathy</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1432/table/mtm.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__mtm.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_mtm.T.molecular_genetic_testing_used_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_mtm.T.molecular_genetic_testing_used_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_mtm.T.molecular_genetic_testing_used_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_mtm.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>MTM1</i></td><td headers="hd_h_mtm.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3,&#x000a0;4</sup></td><td headers="hd_h_mtm.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~90%&#x000a0;<sup>5,&#x000a0;6</sup></td></tr><tr><td headers="hd_h_mtm.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>7</sup></td><td headers="hd_h_mtm.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~10%&#x000a0;<sup>8</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="mtm.TF.1.1"><p class="no_margin">See <a href="/books/NBK1432/#mtm.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="mtm.TF.1.2"><p class="no_margin">See <a href="#mtm.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="mtm.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="mtm.TF.1.4"><p class="no_margin">Lack of amplification by <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> prior to <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> can suggest a putative (multi)<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> on the X <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males; confirmation requires additional testing by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>.</p></div></dd><dt>5. </dt><dd><div id="mtm.TF.1.5"><p class="no_margin"><a class="bk_pop" href="#mtm.REF.de_gouyon.1997.1499">de Gouyon et al [1997]</a>, <a class="bk_pop" href="#mtm.REF.laporte.1997.1505">Laporte et al [1997]</a>, <a class="bk_pop" href="#mtm.REF.herman.2002.114">Herman et al [2002]</a>, <a class="bk_pop" href="#mtm.REF.tsai.2005.245">Tsai et al [2005]</a></p></div></dd><dt>6. </dt><dd><div id="mtm.TF.1.6"><p class="no_margin">The occurrence of deep <a class="def" href="/books/n/gene/glossary/def-item/intronic/">intronic</a> pathogenic variants has been described [<a class="bk_pop" href="#mtm.REF.tosch.2010.375">Tosch et al 2010</a>, <a class="bk_pop" href="#mtm.REF.alhashim.2017.e182">Al-Hashim et al 2017</a>]; these inform the choice of molecular testing method.</p></div></dd><dt>7. </dt><dd><div id="mtm.TF.1.7"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>8. </dt><dd><div id="mtm.TF.1.8"><p class="no_margin"><a class="bk_pop" href="#mtm.REF.laporte.2000.393">Laporte et al [2000]</a>, <a class="bk_pop" href="#mtm.REF.amburgey.2013b.214">Amburgey et al [2013b]</a>, <a class="bk_pop" href="#mtm.REF.oliveira.2013.540">Oliveira et al [2013]</a></p></div></dd></dl></div></div></div></div></div></div><div id="mtm.Clinical_Characteristics"><h2 id="_mtm_Clinical_Characteristics_">Clinical Characteristics</h2><div id="mtm.Clinical_Description"><h3>Clinical Description</h3><p>The clinical characteristics and disease course of <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> myotubular myopathy (X-MTM) have been described in two retrospective natural history studies including nearly 200 genetically confirmed probands [<a class="bk_pop" href="#mtm.REF.amburgey.2017.1355">Amburgey et al 2017</a>, <a class="bk_pop" href="#mtm.REF.beggs.2018.550">Beggs et al 2018</a>]. One study included a prospective one-year survey in addition to retrospective analysis [<a class="bk_pop" href="#mtm.REF.amburgey.2017.1355">Amburgey et al 2017</a>].</p><p>Following isolation of <i>MTM1</i> in 1996, <a class="bk_pop" href="#mtm.REF.herman.1999.206">Herman et al [1999]</a> described a clinical classification for the broader <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Individuals with <i>MTM1</i> pathogenic variants were classified as having one of the following:</p><ul><li class="half_rhythm"><div><b>Severe (classic) X-MTM.</b> Characteristic facies, chronic ventilator dependence, delayed gross motor milestones, inability to independently ambulate, and high incidence of death in infancy. This is by far the most common form of the disease (~80% of all individuals with X-MTM).</div></li><li class="half_rhythm"><div><b>Moderate X-MTM.</b> Less severely delayed motor milestones than in the severe form, prolonged periods of decreased ventilatory support</div></li><li class="half_rhythm"><div><b>Mild X-MTM.</b> Ambulatory with minimally delayed motor milestones, chronic ventilatory support not required beyond the newborn period, and no/limited impact on life span</div></li></ul><p>Since publication of the phenotypic classification by <a class="bk_pop" href="#mtm.REF.herman.1999.206">Herman et al [1999]</a>, a rare adult-onset form with slowly progressive myopathy and no clinical manifestations in infancy has been identified [<a class="bk_pop" href="#mtm.REF.hoffjan.2006.749">Hoffjan et al 2006</a>]. In addition, manifesting female heterozygotes are increasingly reported [<a class="bk_pop" href="#mtm.REF.biancalana.2017.889">Biancalana et al 2017</a>, <a class="bk_pop" href="#mtm.REF.felice.2018.339">Felice et al 2018</a>].</p><div id="mtm.SevereClassic_XMTM"><h4>Severe/Classic X-MTM</h4><p>In males with the severe/classic <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>, polyhydramnios and decreased fetal movement are frequently reported. Premature delivery is described in approximately one third of males [<a class="bk_pop" href="#mtm.REF.beggs.2018.550">Beggs et al 2018</a>]. Hypotonia, extremity weakness, and respiratory distress are present during the newborn period. Ventilatory support is required due to respiratory failure [<a class="bk_pop" href="#mtm.REF.amburgey.2017.1355">Amburgey et al 2017</a>, <a class="bk_pop" href="#mtm.REF.beggs.2018.550">Beggs et al 2018</a>]. Hypoxic events may occur, leading to an acquired hypoxic ischemic encephalopathy. Prolonged ventilator dependence leads to an increased risk of respiratory infection, hypoventilation, and hypoxia.</p><p>Affected infants often have typical myopathic facies with dolichocephaly, high forehead, long face with midface retrusion, prominent eyes, narrow high-arched palate, and severe malocclusion. Ophthalmoparesis is also frequently observed. Additional features include length greater than the 90th centile with a proportionately lower weight (60% of infants), long fingers and/toes (43%), cryptorchidism and/or undescended testicle (&#x0003e;50%), contractures including clubfeet (30%), and areflexia (60%).</p><p>Most infants require lengthy NICU hospitalizations, with approximately 30%-50% of the first year spent in the hospital. Many infants with severe/classic X-MTM succumb to complications of the disorder. The percentage of infants that do not survive the first year of life has been difficult to determine. The reported causes of death are <a class="def" href="/books/n/gene/glossary/def-item/multifactorial/">multifactorial</a>, and include removal of ventilatory support. Approximately 25% of male infants die in the first year of life.</p><p>Most surviving males are discharged home on 24-hour ventilatory support via tracheostomy and gastrostomy tube feedings. In one study including all forms of X-MTM, 85% of individuals required ventilatory and G-tube support, and nearly all needed wheelchair support for ambulation [<a class="bk_pop" href="#mtm.REF.amburgey.2017.1355">Amburgey et al 2017</a>]. The estimated rate of mortality is 10% per year after age one, with few individuals surviving to adulthood. The cause of death is usually related to respiratory failure, though very rarely may be associated with hepatic peliosis.</p><p>The muscle disease may not be progressive. A prospective study of the ventilatory support requirements of 33 individuals over one year showed little change. Prospective analysis of muscle function in a small pilot group also detected no large changes over a one-year period [<a class="bk_pop" href="#mtm.REF.amburgey.2017.1355">Amburgey et al 2017</a>].</p><p>Interestingly, and despite the severe disability and technology dependence of the disease, the annual rate of nonelective hospitalization after the first year of life is not as high as would be expected. In a prospective study of 33 individuals, the rate was 1.1 emergency room visits per year [<a class="bk_pop" href="#mtm.REF.amburgey.2017.1355">Amburgey et al 2017</a>]. The rate of hospitalization is higher in very young individuals (age 1-2 years) [<a class="bk_pop" href="#mtm.REF.amburgey.2017.1355">Amburgey et al 2017</a>, <a class="bk_pop" href="#mtm.REF.beggs.2018.550">Beggs et al 2018</a>].</p><p>Additional features of the underlying myopathy are ophthalmoplegia, ptosis, and severe myopia. Dental malocclusion (requiring orthodontic care) may occur. Constipation is common. Scoliosis often develops in later childhood (75% of individuals in one study) and may require surgical intervention, though scoliosis surgery is documented in only a minority of individuals (&#x02264;10%). Scoliosis can exacerbate respiratory insufficiency, in some cases causing ventilator-independent males to become ventilator dependent again as it progresses. Additional orthopedic manifestations include hip dysplasia and long bone fractures [<a class="bk_pop" href="#mtm.REF.cahill.2007.98">Cahill et al 2007</a>].</p><p><b>Hepatic peliosis.</b> Liver hemorrhage due to hepatic peliosis is perhaps the most serious non-muscle-related complication in X-MTM. Several individuals have died following prolonged liver hemorrhage or hemorrhage into the peritoneal cavity due to hepatic peliosis, a rare vascular lesion characterized by the presence of multiple blood-filled cysts within the liver [<a class="bk_pop" href="#mtm.REF.motoki.2013.917">Motoki et al 2013</a>]. This complication may occur in up to 5% of individuals.</p><p><b>Growth and pubertal development.</b> Despite chronic illness and prolonged ventilator dependence, many individuals with X-MTM have linear growth above the 50th centile, with some individuals achieving greater than the 90th centile for height. Advanced bone age and/or premature adrenarche have been documented in several young males. However, endocrinologic studies performed on several individuals have been normal. Puberty has occurred normally in the few males who have reached adulthood.</p><p><b>Cognition.</b> A recent natural history study identified that many children require special education for learning/cognitive impairments [<a class="bk_pop" href="#mtm.REF.amburgey.2017.1355">Amburgey et al 2017</a>]. This may be due to comorbid hypoxic ischemic encephalopathy, and there are rare individuals with central nervous system complications [<a class="bk_pop" href="#mtm.REF.mccrea.2009.483">McCrea et al 2009</a>]. However, determination of whether there is a primary cognitive component to the disorder awaits further study.</p><p><b>Other.</b> Several medical problems unrelated to the muscle disorder have been reported at low frequency. It is not entirely clear if these are due to <i>MTM1</i> pathogenic variants or unrelated comorbidities. They include pyloric stenosis (~5%), gastroesophageal reflux (10%), cardiac arrhthymias (10%; severity is unclear), gallstones (9%), kidney stones (10%), and elevated liver function tests (20%). <a class="bk_pop" href="#mtm.REF.herman.1999.206">Herman et al [1999]</a> also identified some individuals with a mild form of spherocytosis and a vitamin K-responsive bleeding diathesis. These have not been recently reported and their presence in this population is unknown.</p></div><div id="mtm.Mild_and_Moderate_XMTM"><h4>Mild and Moderate X-MTM</h4><p>At least three reports of multigenerational families with <i>MTM1</i> pathogenic variants and a much milder <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> have been described [<a class="bk_pop" href="#mtm.REF.barth.1998.49">Barth &#x00026; Dubowitz 1998</a>, <a class="bk_pop" href="#mtm.REF.biancalana.2003.135">Biancalana et al 2003</a>, <a class="bk_pop" href="#mtm.REF.yu.2003.148">Yu et al 2003</a>, <a class="bk_pop" href="#mtm.REF.hoffjan.2006.749">Hoffjan et al 2006</a>]. In the recent natural history study, 13% of study subjects could walk independently and were thus considered in the mild/moderate category; 2% required no support for ambulation, ventilation, or feeding.</p><p>Males with moderate or even mild disease are at increased risk for respiratory decompensation with intercurrent illness and may require transient or increased ventilatory support. They are also at risk for some of the same medical complications (including peliosis hepatis) as those with severe X-MTM [<a class="bk_pop" href="#mtm.REF.herman.1999.206">Herman et al 1999</a>]. Most still require some respiratory support (which may be noninvasive), and typically also require feeding assistance.</p><p>There are several case reports describing adult males with mild disease and pathogenic variants in <i>MTM1</i>. These include two individuals in their 60s at the time of publication who first manifested limb girdle weakness after childhood (first symptoms age 18 and 52 years, respectively) [<a class="bk_pop" href="#mtm.REF.biancalana.2003.135">Biancalana et al 2003</a>, <a class="bk_pop" href="#mtm.REF.hoffjan.2006.749">Hoffjan et al 2006</a>]. At least one of these males had facial weakness and ophthalmoparesis. <a class="bk_pop" href="#mtm.REF.yu.2003.148">Yu et al [2003]</a> described two males with a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>MTM1</i>, age 55 and 30 years, both of whom live independently. The 30-year-old developed some muscle weakness later in life and had decreased muscle bulk that was improved by diet and weight-lifting exercises.</p><p><b>Heterozygous females</b> are generally asymptomatic, although symptomatic <a class="def" href="/books/n/gene/glossary/def-item/heterozygote/">heterozygote</a> females have been described [<a class="bk_pop" href="#mtm.REF.savarese.2016.292">Savarese et al 2016</a>, <a class="bk_pop" href="#mtm.REF.biancalana.2017.889">Biancalana et al 2017</a>, <a class="bk_pop" href="#mtm.REF.felice.2018.339">Felice et al 2018</a>]. Severity is variable, and some present with severe infantile weakness resembling that seen in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males. More commonly, symptoms include mild/moderate asymmetric limb weakness and asymmetric reduction of muscle bulk in the correspondingly affected limbs. Facial weakness, ptosis, and ophthalmoparesis are often present. Respiratory failure is not uncommon, and can be unrecognized at the time of presentation.</p><p><b>Histopathologic features</b> [<a class="bk_pop" href="#mtm.REF.lawlor.2016.102">Lawlor et al 2016</a>]</p><ul><li class="half_rhythm"><div>The characteristic muscle biopsy demonstrates numerous small, rounded myofibers with varying percentages of centrally located nuclei. The myofiber size may be uniform throughout the tissue, which may lead to underestimation of the decreased myofiber size (as there may be no appropriately sized fibers for comparison). No diagnostic threshold of central nuclei has been established, as the percentage may increase over time. In rare instances, centrally located nuclei may be absent [<a class="bk_pop" href="#mtm.REF.pierson.2007.562">Pierson et al 2007</a>]. The combination of small myofiber size and central nucleation may result in the central nuclei comprising the majority of the cross-sectional area in some myofibers, which is not specific for X-MTM but is characteristic of severe centronuclear myopathies in very young individuals.</div></li><li class="half_rhythm"><div>Periodic acid-Schiff (PAS) and nicotinamide adenine dinucleotide dehydrogenase-tetrazolium reductase histochemical staining often demonstrate an accumulation of staining product in the center of the small myofibers, reflecting (respectively) maldistribution of glycogen and mitochondria/sarcotubular organelles [<a class="bk_pop" href="#mtm.REF.romero.2010.223">Romero 2010</a>]. In some cases, a particularly striking subsarcolemmal halo will be seen around these aggregates.</div></li><li class="half_rhythm"><div>ATPase histochemical staining may show type 1 myofiber predominance or small type 1 and type 2A fibers alongside relatively larger type 2B fibers [<a class="bk_pop" href="#mtm.REF.pierson.2005.555">Pierson et al 2005</a>]. All fiber types tend to show some degree of decreased myofiber size in most biopsies, however, and appropriately sized or large fibers may be rare or absent. In some biopsies, ATPase staining demonstrates myofibers with central clearing that results from a focal absence of myofibrils [<a class="bk_pop" href="#mtm.REF.romero.2010.223">Romero 2010</a>].</div></li><li class="half_rhythm"><div>The histopathologic findings listed are not specific to X-MTM and may be encountered in <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> myotonic dystrophy type 1 (see <a href="#mtm.Differential_Diagnosis">Differential Diagnosis</a>) and in early-onset <a class="def" href="/books/n/gene/glossary/def-item/autosomal/">autosomal</a> forms of centronuclear myopathy. X-MTM with a low percentage of central nuclei and type 1 fiber predominance can also resemble congenital fiber type disproportion [<a class="bk_pop" href="#mtm.REF.pierson.2005.555">Pierson et al 2005</a>].</div></li></ul><p>Note: (1) The clinical and histopathologic features of <i>MTM1-</i>associated myopathies are broad, requiring that a distinction be made between central and internal nuclei [<a class="bk_pop" href="#mtm.REF.romero.2010.223">Romero 2010</a>]. The former occur at (or very near) the exact center of a myofiber and are typical of (although not specific for) X-MTM, whereas the latter are usually eccentrically situated within the myofiber and may alternatively be associated with other centronuclear myopathies or with chronic myofiber regeneration. (2) Necklace fibers are a distinctive feature that has been described in males with <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> late-onset X-MTM as well as in manifesting <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females [<a class="bk_pop" href="#mtm.REF.biancalana.2017.889">Biancalana et al 2017</a>]. Necklace fibers appear on hematoxylin-eosin-stained sections as a basophilic ring-like deposit that follows the contour of the myofiber and aligns with internal myonuclei. They can also be visualized with succinate dehydrogenase histochemical staining [<a class="bk_pop" href="#mtm.REF.bevilacqua.2009.283">Bevilacqua et al 2009</a>]. Necklace fibers may be accompanied by muscle hypotrophy and type 1 fiber predominance. The percentage of myofibers with internal nuclei frequently exceeds the percentage of fibers with central nuclei and both tend to increase with age. (3) Biopsies from older individuals may feature increased connective and adipose tissues.</p><p><b>Immunohistochemical stains</b> on most (not all) muscle samples from individuals with X-MTM demonstrate persistence of fetal-specific muscle proteins or <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a> such as desmin, vimentin, and fetal myosin [<a class="bk_pop" href="#mtm.REF.sarnat.1990.109">Sarnat 1990</a>, <a class="bk_pop" href="#mtm.REF.sewry.1998.394">Sewry 1998</a>]. Variation in the immunohistochemical expression of NCAM, utrophin, laminin, alpha 5, and HLA1 antigen has also been described [<a class="bk_pop" href="#mtm.REF.helliwell.1998.152">Helliwell et al 1998</a>]. The clinical utility of these immunostains has not been systematically studied.</p><p>T-tubule disorganization visualized through immunohistochemistry has been described in X-MTM [<a class="bk_pop" href="#mtm.REF.alqusairi.2009.18763">Al-Qusairi et al 2009</a>, <a class="bk_pop" href="#mtm.REF.dowling.2009.e1000372">Dowling et al 2009</a>]. DHPRa1, a T-tubule protein, and RyR1, a sarcoplasmic recticulum protein, are abnormally distributed in myofibers with increased immunoreactivity appearing in the center of small fibers [<a class="bk_pop" href="#mtm.REF.dowling.2009.e1000372">Dowling et al 2009</a>]. Levels of both proteins are also diminished, as demonstrated by western blot analysis [<a class="bk_pop" href="#mtm.REF.bachmann.2017.320">Bachmann et al 2017</a>]. Since other centronuclear myopathies also have T-tubule defects, the specific diagnostic utility of this finding may be limited [<a class="bk_pop" href="#mtm.REF.toussaint.2011.253">Toussaint et al 2011</a>].</p><p><b>Electron microscopy.</b> Ultrastructurally, X-MTM is characterized by the disorganization or decreased number of triads (interfaces between the sarcotubular reticulum and T-tubules) in longitudinal sections. This has been well demonstrated in human patients and animal models of disease [<a class="bk_pop" href="#mtm.REF.alqusairi.2009.18763">Al-Qusairi et al 2009</a>, <a class="bk_pop" href="#mtm.REF.dowling.2009.e1000372">Dowling et al 2009</a>, <a class="bk_pop" href="#mtm.REF.childers.2014.220ra10">Childers et al 2014</a>], and quantitative studies have been performed in some animal treatment studies to assist in the evaluation of therapeutic efficacy [<a class="bk_pop" href="#mtm.REF.lawlor.2013.1525">Lawlor et al 2013</a>, <a class="bk_pop" href="#mtm.REF.lawlor.2016.102">Lawlor et al 2016</a>, <a class="bk_pop" href="#mtm.REF.mack.2017.839">Mack et al 2017</a>]. These quantitative studies have been highly controlled in the collection and processing of the tissue, however, and quantification of triads or sarcotubular elements in the clinical diagnostic setting is not feasible.</p><p><b>Immunologic testing</b> using antibodies specific for myotubularin, the protein encoded by <i>MTM1</i> [<a class="bk_pop" href="#mtm.REF.laporte.2001b.42">Laporte et al 2001b</a>], can detect the presence or absence of myotubularin in cell lines from <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals. In 21/24 males with known pathogenic variants, including some <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants, no myotubularin was detected on western blot. One out of five boys with suspected X-MTM in whom no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> was identified also had no detectable protein by western analysis. <a class="bk_pop" href="#mtm.REF.tosch.2010.375">Tosch et al [2010]</a> demonstrated the absence of detectable protein in eight affected individuals with severe to intermediate phenotypes and a decreased amount of protein in an individual with a mild <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Eight of nine individuals had confirmed <i>MTM1</i> pathogenic variants; one individual had no detectable protein and an intermediate phenotype, but no <i>MTM1</i> pathogenic variant was detected. While immunologic testing may be helpful in some individuals with suspected X-MTM in whom no pathogenic variant is found, such analysis is not routine, and adequate antibodies to myotubularin are not widely available.</p></div></div><div id="mtm.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>X-MTM is most frequently caused by <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, frameshift, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants that predict loss of function. Pathogenic variants are found throughout the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> with no concentration in any specific <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a>.</p><ul><li class="half_rhythm"><div>Nonsense and frameshift variants nearly always result in the severe/classic X-MTM <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</div></li><li class="half_rhythm"><div>Splice site and <a class="def" href="/books/n/gene/glossary/def-item/intronic/">intronic</a> variants may cause the severe presentation or can be associated with the milder <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</div></li><li class="half_rhythm"><div>Missense variants can be associated with both severe and mild/moderate phenotypes.</div></li><li class="half_rhythm"><div>Variants associated with the phosphatase <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> and the SET-interacting domain nearly always cause a severe <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Pathogenic variants outside of these two domains are more likely to be associated with milder phenotypes [<a class="bk_pop" href="#mtm.REF.amburgey.2017.1355">Amburgey et al 2017</a>, <a class="bk_pop" href="#mtm.REF.beggs.2018.550">Beggs et al 2018</a>].</div></li><li class="half_rhythm"><div>A large number of pathogenic variants occur in hypermutable CpG dinucleotides; the most common is variant <a class="figpopup" href="/books/NBK1432/table/mtm.T.mtm1_variants_discussed_in_this_ge/?report=objectonly" target="object" rid-figpopup="figmtmTmtm1variantsdiscussedinthisge" rid-ob="figobmtmTmtm1variantsdiscussedinthisge">c.1261-10A&#x0003e;G</a> in <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> 11, which activates a cryptic <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> and produces an <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> <a class="def" href="/books/n/gene/glossary/def-item/insertion/">insertion</a> of three amino acids in the core of the protein tyrosine phosphatase (PTP) site. This <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is associated with a severe <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in males.</div></li></ul></div><div id="mtm.Penetrance"><h3>Penetrance</h3><p>Penetrance is thought to be 100% in males with a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>MTM1</i>, as all have shown findings of the disease. However, disease severity can range from mild to severe.</p><p>Carrier females are generally asymptomatic, though an increasing number of manifesting heterozygotes are being identified [<a class="bk_pop" href="#mtm.REF.savarese.2016.292">Savarese et al 2016</a>, <a class="bk_pop" href="#mtm.REF.biancalana.2017.889">Biancalana et al 2017</a>, <a class="bk_pop" href="#mtm.REF.felice.2018.339">Felice et al 2018</a>].</p></div><div id="mtm.Nomenclature"><h3>Nomenclature</h3><p>X-MTM (or myotubular myopathy or <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> centronuclear myopathy [X-CNM]) is considered a subtype of centronuclear myopathy based on the centrally located nuclei of muscle fibers on histologic examination, and based on shared pathogenic mechanisms. Autosomal dominant and <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> centronuclear myopathy should not be referred to as myotubular myopathy.</p><p>Males with X-MTM with identifiable pathogenic variants in <i>MTM1</i> are said to have <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> myotubular myopathy or simply myotubular myopathy (MTM). This term should only be used to refer to individuals with documented or presumed <i>MTM1</i> pathogenic variants.</p></div><div id="mtm.Prevalence"><h3>Prevalence</h3><p>It has been estimated that X-MTM affects approximately one in 50,000 newborn males [<a class="bk_pop" href="#mtm.REF.laporte.2001a.221">Laporte et al 2001a</a>]; careful, large studies attempting complete ascertainment have not been published.</p></div></div><div id="mtm.Genetically_Related_Allelic_Disorder"><h2 id="_mtm_Genetically_Related_Allelic_Disorder_">Genetically Related (Allelic) Disorders</h2><p>No other <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> is known to be associated with pathogenic variants in <i>MTM1</i>.</p></div><div id="mtm.Differential_Diagnosis"><h2 id="_mtm_Differential_Diagnosis_">Differential Diagnosis</h2><div id="mtm.T.disorders_to_consider_in_the_diffe" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Disorders to Consider in the Differential Diagnosis of X-Linked Myotubular Myopathy</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1432/table/mtm.T.disorders_to_consider_in_the_diffe/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__mtm.T.disorders_to_consider_in_the_diffe_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_1" style="text-align:left;vertical-align:middle;">Disorder</th><th id="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_2" style="text-align:left;vertical-align:middle;">Gene(s)</th><th id="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_3" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_4" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Clinical Features of This Disorder</th></tr><tr><th headers="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_4" id="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Overlapping w/X-MTM</th><th headers="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_4" id="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Distinguishing from X-MTM</th></tr></thead><tbody><tr><td headers="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/myotonic-d/">Congenital myotonic dystrophy type 1</a></td><td headers="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>DMPK</i></td><td headers="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Polyhydramnios</div></li><li class="half_rhythm"><div>Decreased fetal movements</div></li><li class="half_rhythm"><div>Hypotonia</div></li><li class="half_rhythm"><div>Myopathic facies</div></li><li class="half_rhythm"><div>Respiratory distress</div></li><li class="half_rhythm"><div>ID</div></li><li class="half_rhythm"><div>Muscle biopsy possibly indistinguishable</div></li></ul>
</td><td headers="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Absence of ophthalmoparesis</div></li><li class="half_rhythm"><div>AD family history</div></li></ul>
</td></tr><tr><td headers="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>DNM2</i>-related CNM<br />(OMIM <a href="https://omim.org/entry/160150" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">160150</a>)</td><td headers="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>DNM2</i></td><td headers="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Hypotonia</div></li><li class="half_rhythm"><div>Diffuse muscle weakness</div></li><li class="half_rhythm"><div>Ptosis</div></li><li class="half_rhythm"><div>Ophthalmoparesis</div></li><li class="half_rhythm"><div>Myopathic facies</div></li><li class="half_rhythm"><div>Muscle biopsy w/central nuclei</div></li></ul>
</td><td headers="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Clinical features possibly less severe</div></li><li class="half_rhythm"><div>Normal/reduced growth parameters</div></li><li class="half_rhythm"><div>"Spoke on wheel" changes w/oxidative stains on muscle biopsy</div></li></ul>
</td></tr><tr><td headers="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>RYR1</i>-related CNM&#x000a0;<sup>1</sup></td><td headers="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>RYR1</i></td><td headers="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Neonatal hypotonia</div></li><li class="half_rhythm"><div>Weakness</div></li><li class="half_rhythm"><div>Ophthalmoparesis</div></li><li class="half_rhythm"><div>Ptosis</div></li><li class="half_rhythm"><div>Myopathic facies</div></li><li class="half_rhythm"><div>Severe respiratory compromise</div></li><li class="half_rhythm"><div>Muscle biopsy w/central nuclei</div></li></ul>
</td><td headers="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Clinical features possibly less severe</div></li><li class="half_rhythm"><div>Normal/reduced growth parameters</div></li><li class="half_rhythm"><div>May have other non-MTM features on biopsy (cores, dystrophic changes)</div></li></ul>
</td></tr><tr><td headers="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>BIN1</i>-related CNM<br />(OMIM <a href="https://www.omim.org/entry/255200" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">255200</a>)</td><td headers="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>BIN1</i></td><td headers="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Onset in infancy possible</div></li><li class="half_rhythm"><div>Muscle biopsy w/central nuclei</div></li></ul>
</td><td headers="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Clinical features less severe</div></li><li class="half_rhythm"><div>Normal growth parameters</div></li></ul>
</td></tr><tr><td headers="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SPEG-</i>related CNM<br />(OMIM <a href="https://www.omim.org/entry/615959" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">615959</a>)</td><td headers="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SPEG1</i></td><td headers="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Onset in infancy</div></li><li class="half_rhythm"><div>Diffuse weakness</div></li><li class="half_rhythm"><div>Respiratory failure</div></li><li class="half_rhythm"><div>Ophthalmoparesis</div></li><li class="half_rhythm"><div>Muscle biopsy w/central nuclei</div></li></ul>
</td><td headers="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Can have prominent cardiac involvement</div></li><li class="half_rhythm"><div>Biopsies may lack central nuclei</div></li></ul>
</td></tr><tr><td headers="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Nemaline myopathy<br />(OMIM <a href="https://omim.org/phenotypicSeries/PS161800" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PS161800</a>)</td><td headers="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;10 genes</td><td headers="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD<br />AR</td><td headers="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Can present w/diffuse weakness starting in infancy, often w/prominent facial weakness</div></li><li class="half_rhythm"><div>Biopsies can feature myofiber hypotrophy &#x00026; type I fiber predominance.</div></li></ul>
</td><td headers="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Ophthalmoparesis is rare (except in <i>LMOD3</i>-related nemaline myopathy).</div></li><li class="half_rhythm"><div>Muscle biopsy showing nemaline rod aggregates (essentially never seen in X-MTM)</div></li><li class="half_rhythm"><div>Central nuclei usually not increased</div></li></ul>
</td></tr><tr><td headers="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Multiminicore disease (OMIM <a href="https://omim.org/entry/606210" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">606210</a>, <a href="https://omim.org/entry/180901" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">180901</a>)</td><td headers="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SEPN1</i><br /><i>RYR1</i></td><td headers="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR&#x000a0;<sup>2</sup></td><td headers="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>May present w/diffuse weakness starting from birth</div></li><li class="half_rhythm"><div>Ophthalmoparesis in a subset of individuals</div></li></ul>
</td><td headers="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Weakness usually less than in X-MTM</div></li><li class="half_rhythm"><div>Muscle biopsy showing characteristic disruptions of mitochondrial &#x00026; sarcotubular organization on oxidative stains (i.e., cores)</div></li><li class="half_rhythm"><div>Central nuclei usually not increased</div></li></ul>
</td></tr><tr><td headers="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/cms/">Congenital myasthenic syndromes</a></td><td headers="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;25 genes</td><td headers="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD<br />AR</td><td headers="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Can present w/similar symptoms in early childhood, w/facial &#x00026; extremity weakness &#x00026; involvement of extraocular muscles</div></li><li class="half_rhythm"><div>Both conditions may respond to mestinon.</div></li><li class="half_rhythm"><div>Electrodiagnostic features of CMS (abnormal repetitive stimulation &#x00026; jitter on single-fiber EMG) may be seen in X-MTM.</div></li></ul>
</td><td headers="hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_mtm.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Fluctuating weakness variably present in CMS (not typical of X-MTM)</div></li><li class="half_rhythm"><div>Biopsies are either normal or show nonspecific changes; the features of X-MTM are not seen on biopsy in CMS.</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; AR = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>; CNM = centronuclear myopathy; ID = intellectual disability; MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a>; MTM = myotubular myopathy</p></div></dd><dt>1. </dt><dd><div id="mtm.TF.2.1"><p class="no_margin"><a class="bk_pop" href="#mtm.REF.wilmshurst.2010.717">Wilmshurst et al [2010]</a>, <a class="bk_pop" href="#mtm.REF.amburgey.2013a.117">Amburgey et al [2013a]</a></p></div></dd><dt>2. </dt><dd><div id="mtm.TF.2.2"><p class="no_margin">The occurrence of minicore myopathy in two generations in a few families &#x02013; suggestive of <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> inheritance &#x02013; has been reported.</p></div></dd></dl></div></div></div><p>See <a href="https://omim.org/phenotypicSeries/PS160150" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Myopathy, centronuclear: OMIM Phenotypic Series</a> to view genes associated with this <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in OMIM.</p></div><div id="mtm.Management"><h2 id="_mtm_Management_">Management</h2><div id="mtm.Evaluations_Following_Initial_Diagno"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> myotubular myopathy (X-MTM), the following evaluations are recommended if they have not already been completed:</p><ul><li class="half_rhythm"><div>Assessment of pulmonary function for long-term ventilatory management, either during initial hospitalization (if presentation at birth) or after the diagnosis has been established.</div></li><li class="half_rhythm"><div>Feeding/swallowing assessment, as performed by a qualified occupational therapist or equivalent allied health professional</div></li><li class="half_rhythm"><div>Ophthalmologic evaluation, either during initial hospitalization (if presentation at birth) or after the diagnosis has been established</div></li><li class="half_rhythm"><div>In individuals with hemolysis or unexplained anemia, osmotic fragility test to detect spherocytosis</div></li><li class="half_rhythm"><div>In the presence of infantile vomiting, investigation for pyloric stenosis</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li><li class="half_rhythm"><div>In older children, evaluation for orthopedic complications, including examination for scoliosis</div></li></ul></div><div id="mtm.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Management of individuals with X-MTM is based on supportive care measures and in large part is similar to that for other <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> myopathies [<a class="bk_pop" href="#mtm.REF.wang.2012.363">Wang et al 2012</a>]. Management optimally involves a team of specialists with expertise in the long-term care of individuals with neuromuscular disorders. Such teams often include a pulmonologist, neurologist, physical therapist and/or rehabilitation medicine specialist, and clinical geneticist.</p><p>Once the specific diagnosis of X-MTM is confirmed, management may be guided by family decisions regarding continued ventilatory support for the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member. Families may benefit from the involvement of professionals familiar with the data concerning the overall prognosis for X-MTM. Talking with other families who have children with the disorder can be extremely helpful, as can discussion with members of an MTM family foundation (see <a href="#mtm.Resources">Resources</a>). There is also a patient-/family-oriented guide for care for X-MTM.</p><ul><li class="half_rhythm"><div>Given the risks for aspiration pneumonia and respiratory failure in infants with moderate or severe disease, tracheostomy and G-tube feeding should be seriously considered. Even individuals with mild disease are at risk for significant morbidity and mortality from intercurrent respiratory infection and hypoventilation.</div></li><li class="half_rhythm"><div>For ventilator-dependent individuals, communication support incorporates speech with a capped tracheostomy or Passy-Muir valve, sign language, and/or communication devices such as writing boards.</div></li><li class="half_rhythm"><div>Affected individuals older than age five years attend school, usually assisted by a dedicated nurse or aide, or have home-based teachers to limit exposure to infectious agents. Based on the emerging natural history study data, neuropsychologic evaluation may help identify learning difficulties and enable optimized educational planning.</div></li><li class="half_rhythm"><div>Ophthalmologists, orthopedists specializing in scoliosis management, and orthodontists should address specific medical complications related to the underlying myopathy.</div></li><li class="half_rhythm"><div>Children with X-MTM and an unexpected decline in motor skills should be evaluated for a potential abnormality in neuromuscular junction (NMJ) function. <a class="bk_pop" href="#mtm.REF.robb.2011.379">Robb et al [2011]</a> identified one individual with mild X-MTM and unexplained decline in motor skills (i.e., lost ambulation) consistent with a disorder of NMJ transmission. On evaluation, this individual was found to have the electrodiagnostic features of NMJ disease (electrodecrement with repetitive stimulation and jitter with single-fiber EMG) but no laboratory evidence to support a co-occurring diagnosis of myasthenia gravis. Subsequent treatment with pyridostigmine resulted in rapid recovery of ambulation.</div></li><li class="half_rhythm"><div>In addition, and even without signs of unexplained decline, individuals with X-MTM may have underlying abnormalities in NMJ structure and function and thus may benefit from treatment targeted at improving NMJ signaling. A preclinical study in a mouse model of X-MTM identified structural abnormalities in the NMJ and demonstrated significant improvement in muscle fatigue with pyridostigmine treatment [<a class="bk_pop" href="#mtm.REF.dowling.2012.852">Dowling et al 2012</a>]. Pyridostigmine has been used "off label" by many individuals with X-MTM, with several anecdotal reports of clinical improvement [Author, personal communication]. The drug, however, has not been systematically studied in individuals with X-MTM; a retrospective study aimed at understanding the potential impact of pyridostigmine on clinical symptoms is ongoing.</div></li></ul></div><div id="mtm.Surveillance"><h3>Surveillance</h3><p>Appropriate surveillance includes the following:</p><ul><li class="half_rhythm"><div>Annual pulmonary assessment, including pulmonary function testing if able to be performed</div></li><li class="half_rhythm"><div>Polysomnography every one to three years unless symptoms of sleep-disordered breathing are present on history</div></li><li class="half_rhythm"><div>Spinal examination for signs of scoliosis, particularly in late childhood and adolescence</div></li><li class="half_rhythm"><div>Annual ophthalmologic exams for ophthalmoplegia, ptosis, myopia, and for protective assessment of the effect of impaired eyelid closure</div></li><li class="half_rhythm"><div>Assessment for dental malocclusion, with referral for orthodontia if indicated</div></li></ul><p>Currently, the risk for non-neurologic events including bleeding diatheses and gastrointestinal complications is uncertain. Furthermore, the benefit of screening for such abnormalities has yet to be determined. Potential screening tests may include the following, though these studies have not been found to reliably identify actionable abnormalities:</p><ul><li class="half_rhythm"><div class="half_rhythm">Annual blood counts [<a class="bk_pop" href="#mtm.REF.herman.1999.206">Herman et al 1999</a>]</div></li><li class="half_rhythm"><div class="half_rhythm">Annual liver function test and abdominal ultrasound to address the potential risk of peliosis hepatis</div><div class="half_rhythm">Note: No advanced screening has been found to be useful for detecting hepatic peliosis prior to the development of clinically significant hemorrhage.</div></li></ul></div><div id="mtm.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>It is generally agreed that neuromuscular paralytics such as succinylcholine should be avoided as part of anesthesia for patients with X-MTM. However, it is important to note that individuals with X-MTM are NOT susceptible to malignant hyperthermia [<a class="bk_pop" href="#mtm.REF.litman.2018.159">Litman et al 2018</a>].</p></div><div id="mtm.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>See <a href="#mtm.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="mtm.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Gene replacement therapy is a promising treatment strategy for X-MTM. AAV-mediated delivery of <i>MTM1</i> is associated with significant improvement in strength, histopathology, and survival in both murine and canine models of the disease [<a class="bk_pop" href="#mtm.REF.childers.2014.220ra10">Childers et al 2014</a>]. A Phase I/II clinical trial (ASPIRO) is currently under way testing the safety and efficacy of this treatment in X-MTM in boys under age four years.</p><p>Several other strategies have shown promise in preclinical models of X-MTM. Lowering of DNM2, a key disease modifier, using either genetic or antisense oligonucleotide-mediated <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> knockdown, resulted in increased strength and prolonged survival in a murine model of X-MTM [<a class="bk_pop" href="#mtm.REF.cowling.2014.1350">Cowling et al 2014</a>, <a class="bk_pop" href="#mtm.REF.tasfaout.2017.15661">Tasfaout et al 2017</a>]. Similarly, genetic knockdown or chemical inhibition of the lipid kinase PIK3C2B both prevented and reversed the disease course in an X-MTM murine model [<a class="bk_pop" href="#mtm.REF.sabha.2016.3613">Sabha et al 2016</a>]. Additional development of treatments based on these data is under way, with a goal of translation to the clinical arena.</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="mtm.Genetic_Counseling"><h2 id="_mtm_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="mtm.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p><a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> myotubular myopathy (X-MTM) is inherited in an X-linked manner.</p></div><div id="mtm.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The father of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male will not have the disorder nor will he be <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> for the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>; therefore, he does not require further evaluation/testing.</div></li><li class="half_rhythm"><div>In a family with more than one <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual, the mother of an affected male is an <a class="def" href="/books/n/gene/glossary/def-item/obligate-heterozygote/">obligate heterozygote</a> (<a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>). Note: If a woman has more than one affected child and no other affected relatives and if the <i>MTM1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> cannot be detected in her leukocyte DNA, she most likely has <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li><li class="half_rhythm"><div>The <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> risk for a woman whose son has a confirmed <i>MTM1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> and is the sole <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male in the family is 80%-90% [<a class="bk_pop" href="#mtm.REF.laporte.2000.393">Laporte et al 2000</a>, <a class="bk_pop" href="#mtm.REF.herman.2002.114">Herman et al 2002</a>, author observation]. Thus, an estimated 10%-20% of affected males who are the only affected individual in the family have <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variants in <i>MTM1</i> and mothers who are not carriers.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to sibs of a male proband depends on the genetic status of the mother.</p><ul><li class="half_rhythm"><div class="half_rhythm">If the mother of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has an <i>MTM1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the chance of transmitting it in each pregnancy is 50%. Males who inherit the pathogenic variant will be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>; females who inherit the pathogenic variant will be heterozygotes and will generally be asymptomatic, although symptomatic <a class="def" href="/books/n/gene/glossary/def-item/heterozygote/">heterozygote</a> females have been described [<a class="bk_pop" href="#mtm.REF.savarese.2016.292">Savarese et al 2016</a>, <a class="bk_pop" href="#mtm.REF.biancalana.2017.889">Biancalana et al 2017</a>, <a class="bk_pop" href="#mtm.REF.felice.2018.339">Felice et al 2018</a>].</div></li><li class="half_rhythm"><div class="half_rhythm">If the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> represents a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case (i.e., a single occurrence in a family) and if the <i>MTM1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> cannot be detected in the leukocyte DNA of the mother, the risk to sibs is greater than that of the general population because of the possibility of maternal <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>. Several instances of maternal germline mosaicism for <i>MTM1</i> pathogenic variants have been described [<a class="bk_pop" href="#mtm.REF.vincent.1998.241">Vincent et al 1998</a>, <a class="bk_pop" href="#mtm.REF.h_ne.1999.77">H&#x000e4;ne et al 1999</a>, <a class="bk_pop" href="#mtm.REF.laporte.2000.393">Laporte et al 2000</a>].</div><div class="half_rhythm">Note: Postzygotic and <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> has been reported in the maternal grandfather of a severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> [<a class="bk_pop" href="#mtm.REF.hedbergoldfors.2017.843">Hedberg-Oldfors et al 2017</a>].</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div><b>Classic/severe X-MTM.</b> In general, <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males with the classic/severe form of X-MTM do not survive to reproductive age. Those who do survive may have reproductive limitations related to physical disability. It is not known if males with severe disease are infertile.</div></li><li class="half_rhythm"><div><b>Mild X-MTM.</b> Affected males with mild X-MTM will pass the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> to all of their daughters and none of their sons. <a class="bk_pop" href="#mtm.REF.biancalana.2003.135">Biancalana et al [2003]</a> reported an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male with mild disease detected at age 20 who fathered two unaffected daughters, both of whom had affected sons. There are other similar unpublished examples related to males with mild disease.</div></li></ul><p><b>Other family members.</b> The <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s maternal aunts may be at risk of being heterozygotes (carriers) for the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, and the aunt's offspring, depending on their gender, may be at risk of being carriers or of being <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</p><p>Note: Molecular genetic testing may be able to identify the family member in whom a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> arose, information that could help determine genetic risk status of the extended family.</p></div><div id="mtm.Heterozygote_Carrier_Detection"><h3>Heterozygote (Carrier) Detection</h3><p>Molecular genetic testing of at-risk female relatives to determine their genetic status is most informative if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</p><p>Note: (1) Females who are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> (carriers) for this <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> disorder are generally asymptomatic, although symptomatic <a class="def" href="/books/n/gene/glossary/def-item/heterozygote/">heterozygote</a> females have been described [<a class="bk_pop" href="#mtm.REF.savarese.2016.292">Savarese et al 2016</a>, <a class="bk_pop" href="#mtm.REF.biancalana.2017.889">Biancalana et al 2017</a>, <a class="bk_pop" href="#mtm.REF.felice.2018.339">Felice et al 2018</a>]. (2) Identification of female heterozygotes requires either: (a) prior identification of the <i>MTM1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family; or, (b) if an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male is not available for testing, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> first by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, and if no pathogenic variant is identified, by <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>.</p></div><div id="mtm.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are heterozygotes (carriers) or are at increased risk of being heterozygotes (carriers).</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="mtm.Prenatal_Testing_and_Preimplantation"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>MTM1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p><p>Several instances of <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> for <i>MTM1</i> pathogenic variants have been described [<a class="bk_pop" href="#mtm.REF.vincent.1998.241">Vincent et al 1998</a>, <a class="bk_pop" href="#mtm.REF.h_ne.1999.77">H&#x000e4;ne et al 1999</a>, <a class="bk_pop" href="#mtm.REF.laporte.2000.393">Laporte et al 2000</a>]. Thus, it is important to discuss the option of prenatal testing in a male fetus even in instances in which the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is not identified in DNA extracted from the mother's leukocytes.</p></div></div><div id="mtm.Resources"><h2 id="_mtm_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Joshua Frase Foundation</b></div><div>PO Box 2041</div><div>Ponte Vedra Beach FL 32004</div><div><b>Phone:</b> 904-607-1358</div><div><b>Fax:</b> 904-273-9818</div><div><b>Email:</b> info@joshuafrase.org</div><div><a href="http://www.joshuafrase.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.joshuafrase.org</a></div></li><li class="half_rhythm"><div><b>MTM-CNM Family Connection, Inc</b></div><div><a href="http://www.mtm-cnm.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.mtm-cnm.org</a></div></li><li class="half_rhythm"><div><b>Where There&#x02019;s A Will There&#x02019;s A Cure</b></div><div><b>Phone:</b> 630-208-1105</div><div><a href="http://www.will-cure.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.will-cure.org</a></div></li><li class="half_rhythm"><div><b>Muscular Dystrophy Association - USA (MDA)</b></div><div>222 South Riverside Plaza</div><div>Suite 1500</div><div>Chicago IL 60606</div><div><b>Phone:</b> 800-572-1717</div><div><b>Email:</b> mda@mdausa.org</div><div><a href="http://www.mda.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.mda.org</a></div></li><li class="half_rhythm"><div><b>Myotubular Trust</b></div><div>United Kingdom</div><div><b>Email:</b> melaniespring@myotubulartrust.org</div><div><a href="http://myotubulartrust.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.myotubulartrust.org</a></div></li><li class="half_rhythm"><div><b>ZNM- Zusammen Stark! e. V. </b></div><div>Germany</div><div><a href="http://www.znm-zusammenstark.org/en/myopathie/author/holger/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.znm-zusammenstark.org/en/myopathie/author/holger/</a></div></li><li class="half_rhythm"><div><b>Congenital Muscle Disease International Registry (CMDIR)</b></div><div><i>The CMDIR is a patient self-report registry with the goal to register the global <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> muscle disease population including persons with congenital myopathy, congenital muscular dystrophy, and congenital myasthenic syndrome. The CMDIR registers <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals of all ages with symptoms from birth through late onset (limb-girdle). Registrants will receive educational information and connections to others in the CMD community, and will be contacted about potential participation in clinical trials for their CMD subtype.</i></div><div>19401 South Vermont Avenue</div><div>Suite J100</div><div>Torrance CA 90502</div><div><b>Phone:</b> 323-250-2399</div><div><b>Fax:</b> 310-684-2023</div><div><b>Email:</b> counselor@cmdir.org; sarah.foye@cmdir.org</div><div><a href="http://www.cmdir.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.cmdir.org</a></div></li><li class="half_rhythm"><div><b>International Family Registry for Centronuclear and Myotubular Myopathies</b></div><div><a href="http://www.joshuafrase.org/get-involved/understanding-your-participation.php" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Joshua Frase Foundation - Family registry for people with CNM/MTM</a></div></li><li class="half_rhythm"><div><b>Myotubular and Centronuclear Myopathy Patient Registry</b></div><div><a href="https://mtmcnmregistry.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.mtmcnmregistry.org</a></div></li></ul></div><div id="mtm.Molecular_Genetics"><h2 id="_mtm_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="mtm.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>X-Linked Myotubular Myopathy: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1432/table/mtm.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__mtm.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_mtm.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_mtm.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_mtm.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_mtm.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_mtm.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_mtm.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_mtm.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/4534" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>MTM1</i></a></td><td headers="hd_b_mtm.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=4534" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Xq28</a></td><td headers="hd_b_mtm.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q13496" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Myotubularin</a></td><td headers="hd_b_mtm.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://databases.lovd.nl/shared/genes/MTM1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MTM1 homepage - Leiden Muscular Dystrophy pages</a></td><td headers="hd_b_mtm.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=MTM1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MTM1</a></td><td headers="hd_b_mtm.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=MTM1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MTM1</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="mtm.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="mtm.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for X-Linked Myotubular Myopathy (<a href="/omim/300415,310400" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1432/table/mtm.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__mtm.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/300415" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">300415</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MYOTUBULARIN; MTM1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/310400" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">310400</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MYOPATHY, CENTRONUCLEAR, X-LINKED; CNMX</td></tr></tbody></table></div></div><p><b>Gene structure.</b>
<i>MTM1</i> is approximately 90 kb in size and comprises 15 exons (<a href="/nuccore/NM_000252.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000252.2</a>). The first <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> is noncoding and encompasses the putative <a class="def" href="/books/n/gene/glossary/def-item/promoter-region/">promoter region</a> of the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>. The start codon is present in exon 2. The gene is ubiquitously expressed and shows a muscle-specific alternative transcript because of the use of a different polyadenylation signal [<a class="bk_pop" href="#mtm.REF.laporte.1996.175">Laporte et al 1996</a>]. For a detailed summary of gene, transcript, and protein information, see <a href="/books/NBK1432/#mtm.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Benign variants.</b> To date, more than 20 benign variants have been identified in <i>MTM1</i> [<a class="bk_pop" href="#mtm.REF.laporte.2000.393">Laporte et al 2000</a>, <a class="bk_pop" href="#mtm.REF.herman.2002.114">Herman et al 2002</a>] (see <a href="/books/NBK1432/#mtm.molgen.TA">Table A</a>, <b>ClinVar</b>). The majority of changes identified represent rare variants, with the exception of c.1260+3G&#x0003e;A, which occurs at a frequency of approximately 50% in the general population [<a class="bk_pop" href="#mtm.REF.laporte.2000.393">Laporte et al 2000</a>].</p><p><b>Pathogenic variants.</b> More than 250 pathogenic variants that cause <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> myotubular myopathy have been described [<a class="bk_pop" href="#mtm.REF.laporte.2000.393">Laporte et al 2000</a>, <a class="bk_pop" href="#mtm.REF.herman.2002.114">Herman et al 2002</a>, <a class="bk_pop" href="#mtm.REF.biancalana.2003.135">Biancalana et al 2003</a>, <a class="bk_pop" href="#mtm.REF.bertini.2004.387">Bertini et al 2004</a>, <a class="bk_pop" href="#mtm.REF.tsai.2005.245">Tsai et al 2005</a>] (see <a href="/books/NBK1432/#mtm.molgen.TA">Table A</a>, <b>Locus-Specific Databases</b> and <b>HGMD</b>). Pathogenic variants are evenly distributed throughout the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>. While some pathogenic variants appear to be recurrent, no predominant common variant has been identified in any population. Interestingly, <i>in silico</i> analyses showed that <i>MTM1</i> had significantly fewer single-nucleotide variants than expected, which predicts that it is extremely intolerant of <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> alleles and relatively intolerant of <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants (see <a href="http://exac.broadinstitute.org/gene/ENSG00000171100" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EXaC database</a>). This echoes the finding that most <i>MTM1</i> variants are rare and disease causing [<a class="bk_pop" href="#mtm.REF.lek.2016.285">Lek et al 2016</a>].</p><p>A large number of pathogenic variants occur in hypermutable CpG dinucleotides and this mechanism may explain the recurrence of some variants. Six recurrent variants account for about 24% of cases in the MTM1-LOVD database [<a class="bk_pop" href="#mtm.REF.oliveira.2013.540">Oliveira et al 2013</a>].</p><div id="mtm.T.mtm1_variants_discussed_in_this_ge" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p><i>MTM1</i> Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1432/table/mtm.T.mtm1_variants_discussed_in_this_ge/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__mtm.T.mtm1_variants_discussed_in_this_ge_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_mtm.T.mtm1_variants_discussed_in_this_ge_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variant Classification</th><th id="hd_h_mtm.T.mtm1_variants_discussed_in_this_ge_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_mtm.T.mtm1_variants_discussed_in_this_ge_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_mtm.T.mtm1_variants_discussed_in_this_ge_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_mtm.T.mtm1_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Benign</b></td><td headers="hd_h_mtm.T.mtm1_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1260+3G&#x0003e;A&#x000a0;<sup>1</sup></td><td headers="hd_h_mtm.T.mtm1_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td><td headers="hd_h_mtm.T.mtm1_variants_discussed_in_this_ge_1_1_1_4" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_000252.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000252<wbr style="display:inline-block"></wbr>​.2</a><br /><a href="/protein/NP_000243.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000243<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_mtm.T.mtm1_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Pathogenic</b></td><td headers="hd_h_mtm.T.mtm1_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1261-10A&#x0003e;G&#x000a0;<sup>2</sup></td><td headers="hd_h_mtm.T.mtm1_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt></dt><dd><div><p class="no_margin">NA = not applicable</p></div></dd><dt>1. </dt><dd><div id="mtm.TF.3.1"><p class="no_margin"><a href="https://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=222410&#x00026;pt=14Ae4UVE011vYPDY_8x2AErL6FFFz9myuCZ5xa-8kheAeF5" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">rs222410</a></p></div></dd><dt>2. </dt><dd><div id="mtm.TF.3.2"><p class="no_margin">See <a href="#mtm.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</a>.</p></div></dd></dl></div></div></div><p><b>Contiguous-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions.</b> Contiguous-gene deletions in individuals with clinical features in addition to those of X-MTM have been reported [<a class="bk_pop" href="#mtm.REF.dahl.1995.1108">Dahl et al 1995</a>, <a class="bk_pop" href="#mtm.REF.hu.1996.139">Hu et al 1996</a>, <a class="bk_pop" href="#mtm.REF.laporte.1997.1505">Laporte et al 1997</a>, <a class="bk_pop" href="#mtm.REF.bartsch.1999.310">Bartsch et al 1999</a>, <a class="bk_pop" href="#mtm.REF.biancalana.2003.135">Biancalana et al 2003</a>, <a class="bk_pop" href="#mtm.REF.tsai.2005.245">Tsai et al 2005</a>].</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>MTM1</i> encodes myotubularin, a protein of 603 amino acids [<a class="bk_pop" href="#mtm.REF.laporte.1996.175">Laporte et al 1996</a>, <a class="bk_pop" href="#mtm.REF.laporte.1998.325">Laporte et al 1998</a>]. The MTM1 protein is composed of the following domains: PH-GRAM (pleckstrin homology-glucosyltransferase / Rab-like GTPase activator / myotubularin) <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a>, PTP (dual specificity and tryosine phosphatase) domain, SID (SET protein interacting domain), and a PEST/PDZ domain.</p><p>Myotubularin functions primarily as a lipid phosphatase [<a class="bk_pop" href="#mtm.REF.taylor.2000.8910">Taylor et al 2000</a>], specifically acting to remove phosphates from the 3-position of phosphoinositides. Studies using both cell-free biochemical assays and exogenous expression in cell culture have shown that myotubularin converts phosphoinositide-3-phosphate (PI3P) to phosphoinositide phosphate (PIP) and phosphoinositide-3,5-bisphosphate (PI3,5P2) to phosphoinositide-5-phosphate (PI5P) [<a class="bk_pop" href="#mtm.REF.taylor.2000.8910">Taylor et al 2000</a>, <a class="bk_pop" href="#mtm.REF.chaussade.2003.2448">Chaussade et al 2003</a>, <a class="bk_pop" href="#mtm.REF.robinson.2006.403">Robinson &#x00026; Dixon 2006</a>]. Myotubularin is also predicted to function as a protein phosphatase, though this activity has not been convincingly demonstrated.</p><p>Myotubularin's cellular function is inferred in part from the known roles of the phosphoinositides upon which it acts and from the fact that it localizes to endosomes [<a class="bk_pop" href="#mtm.REF.laporte.2002.3105">Laporte et al 2002</a>, <a class="bk_pop" href="#mtm.REF.tsujita.2004.13817">Tsujita et al 2004</a>, <a class="bk_pop" href="#mtm.REF.cao.2007.1052">Cao et al 2007</a>, <a class="bk_pop" href="#mtm.REF.dowling.2008.1035">Dowling et al 2008</a>]. In vitro, myotubularin has been demonstrated to regulate the sorting of cargo in and through the endosome through its ability to promote the conversion of phosphoinositides [<a class="bk_pop" href="#mtm.REF.ketel.2016.408">Ketel et al 2016</a>].</p><p>Myotubularin likely has roles in other cellular processes as well. It has been shown to interact with the intermediate filament network and specifically with desmin [<a class="bk_pop" href="#mtm.REF.hnia.2011.70">Hnia et al 2011</a>]. This interaction may both mediate myotubularin localization and also enable myotubularin to participate as a regulator of mitochondrial dynamics. It also interacts as part of a ubiquitin ligase complex that modulates the breakdown of misfolded cytoskeletal components including the desmin filament network [<a class="bk_pop" href="#mtm.REF.gavriilidis.2018.198">Gavriilidis et al 2018</a>]. In addition, much of the protein does not localize to endosomes, but is instead at steady state in a dense cytoplasmic network and can be found transiently at Rac-induced membrane ruffles [<a class="bk_pop" href="#mtm.REF.laporte.2002.3105">Laporte et al 2002</a>]. Importantly, there is a still a gap between the defined functions of myotubularin in cell systems and its role in skeletal muscle development and homeostasis.</p><p>Myotubularin was the first described member of a large group of homologous, evolutionarily conserved proteins [<a class="bk_pop" href="#mtm.REF.raess.2017.49">Raess et al 2017</a>]. To date, 14 myotubularin-related (MTMR) proteins have been characterized [<a class="bk_pop" href="#mtm.REF.robinson.2006.403">Robinson &#x00026; Dixon 2006</a>]; eight have dual-specificity phosphatase activity identical to myotubularin. The remaining have nonfunctional phosphatase domains, and are thought to act as coactivators or regulators of the enzymatically active members of the family. Several MTMRs are critical for mammalian development and human neurologic disease (reviewed by <a class="bk_pop" href="#mtm.REF.raess.2017.49">Raess et al [2017]</a>).</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Pathogenic variants in <i>MTM1</i> result in loss of function or absence of the myotubularin protein. Disease is mediated at least in part by loss of myotubularin's phosphatase activity, as <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants that impair myotubularin's enzymatic activity are associated with the severe/classic <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Pathogenic variants that do not affect the enzymatic <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> support the hypothesis that myotubularin has functions in addition to phosphatase activity [<a class="bk_pop" href="#mtm.REF.amoasii.2012.e1002965">Amoasii et al 2012</a>]. This is further supported by the observation that expression of an <i>MTM1</i> construct without phosphatase activity in <i>Mtm1</i> knockout mice can partially rescue the murine phenotype [<a class="bk_pop" href="#mtm.REF.amoasii.2012.e1002965">Amoasii et al 2012</a>].</p><p>The mechanism(s) whereby lack or dysfunction of myotubularin produces the disease <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> seen in X-MTM have come into focus. Based on data from animal models, the weakness in myotubular myopathy is caused, at least in part, by defective excitation-contraction (E-C) coupling [<a class="bk_pop" href="#mtm.REF.alqusairi.2009.18763">Al-Qusairi et al 2009</a>, <a class="bk_pop" href="#mtm.REF.dowling.2009.e1000372">Dowling et al 2009</a>]. E-C coupling is the process by which electrical stimuli at the neuromuscular junction (NMJ) are translated into muscle contraction. It is mediated by the triad, a structure composed of the T-tubule and the terminal sarcoplasmic reticulum; the triad is responsible for regulated calcium release. Loss of myotubularin results in abnormalities in the structure of the triad as well as impaired stimulus-dependent calcium release early in the disease process, and is likely an early pathogenic event in humans with X-MTM. Interestingly, abnormalities in the E-C coupling apparatus have been observed in the genetically determined <a class="def" href="/books/n/gene/glossary/def-item/autosomal/">autosomal</a> forms of myotubular myopathy, thus suggesting a common pathogenic mechanism for all types of MTM [<a class="bk_pop" href="#mtm.REF.toussaint.2011.253">Toussaint et al 2011</a>, <a class="bk_pop" href="#mtm.REF.jungbluth.2018.151">Jungbluth et al 2018</a>]. The precise mechanism(s) through which loss of MTM1 impairs triad structure and function are not fully elucidated. Furthermore, the relationship between MTM1 function, triad biology, and the presence of the pathognomonic appearance of central nuclei is also unclear. Data suggest that both internal nucleation and triad disorganization may be mediated by altered N-WASP function and its impact on key filamentous networks within the myofiber [<a class="bk_pop" href="#mtm.REF.falcone.2014.1455">Falcone et al 2014</a>, <a class="bk_pop" href="#mtm.REF.roman.2017.1189">Roman et al 2017</a>].</p><p>Loss of myotubularin likely affects other aspects of muscle function as well. In both zebrafish and murine models of X-MTM, disorganization of the NMJ has been reported [<a class="bk_pop" href="#mtm.REF.robb.2011.379">Robb et al 2011</a>]. In the murine model and in cells derived from biopsies of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, abnormal mitochondrial function has been described [<a class="bk_pop" href="#mtm.REF.hnia.2011.70">Hnia et al 2011</a>]. The specific contribution(s) to the disease <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of these changes remain to be determined. Patient muscle cells demonstrate a significant decrease in expression of the ryanodine receptor 1, a decrease in muscle-specific microRNAs, and a considerable upregulation of histone deacetylase-4, which are likely consequent to the primary genetic defect and related to the severe decrease in muscle strength observed in patients [<a class="bk_pop" href="#mtm.REF.bachmann.2017.320">Bachmann et al 2017</a>]. In addition, non-muscle phenotypes have been described in individuals with X-MTM, including unusual growth parameters and the rare occurrence of hepatic peliosis. These features have not been observed in animal models of X-MTM, and thus the mechanisms underlying them have evaded elucidation.</p></div><div id="mtm.References"><h2 id="_mtm_References_">References</h2><div id="mtm.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.alhashim.2017.e182">Al-Hashim A, Gonorazky HD, Amburgey K, Das S, Dowling JJ. A novel intronic mutation in MTM1 detected by RNA analysis in a case of X-linked myotubular myopathy. <span><span class="ref-journal">Neurol Genet. </span>2017;<span class="ref-vol">3</span>:e182.</span> [<a href="/pmc/articles/PMC5570672/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5570672</span></a>] [<a href="/pubmed/28852708" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28852708</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.alqusairi.2009.18763">Al-Qusairi L, Weiss N, Toussaint A, Berby C, Messaddeq N, Kretz C, Sanoudou D, Beggs AH, Allard B, Mandel J-L, Jacquemond V, Buj-Bello A. T-tubule disorganization and defective excitation-contraction coupling in muscle fibers lacking myotubularin lipid phosphatase. <span><span class="ref-journal">Proc Natl Acad Sci (USA). </span>2009;<span class="ref-vol">106</span>:18763–8.</span> [<a href="/pmc/articles/PMC2773964/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2773964</span></a>] [<a href="/pubmed/19846786" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19846786</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.amburgey.2013a.117">Amburgey K, Bailey A, Hwang JH, Tarnopolsky MA, Bonnemann CG, Medne L, Mathews KD, Collins J, Daube JR, Wellman GP, Callaghan B, Clarke NF, Dowling JJ. Genotype-phenotype correlations in recessive RYR1-related myopathies. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2013a;<span class="ref-vol">8</span>:117.</span> [<a href="/pmc/articles/PMC3751094/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3751094</span></a>] [<a href="/pubmed/23919265" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23919265</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.amburgey.2013b.214">Amburgey K, Lawlor MW, Del Gaudio D, Cheng YW, Fitzpatrick C, Minor A, Li X, Aughton D, Das S, Beggs AH, Dowling JJ. Large duplication in MTM1 associated with myotubular myopathy. <span><span class="ref-journal">Neuromuscul Disord. </span>2013b;<span class="ref-vol">23</span>:214–8.</span> [<a href="/pmc/articles/PMC3594803/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3594803</span></a>] [<a href="/pubmed/23273872" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23273872</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.amburgey.2017.1355">Amburgey K, Tsuchiya E, de Chastonay S, Glueck M, Alverez R, Nguyen CT, Rutkowski A, Hornyak J, Beggs AH, Dowling JJ. A natural history study of X-linked myotubular myopathy. <span><span class="ref-journal">Neurology. </span>2017;<span class="ref-vol">89</span>:1355–64.</span> [<a href="/pmc/articles/PMC5649758/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5649758</span></a>] [<a href="/pubmed/28842446" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28842446</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.amoasii.2012.e1002965">Amoasii L, Bertazzi DL, Tronch&#x000e8;re H, Hnia K, Chicanne G, Rinaldi B, Cowling BS, Ferry A, Klaholz B, Payrastre B, Laporte J, Friant S. Phosphatase-dead myotubularin ameliorates X-linked centronuclear myopathy phenotypes in mice. <span><span class="ref-journal">PLoS Genet. </span>2012;<span class="ref-vol">8</span>:e1002965.</span> [<a href="/pmc/articles/PMC3469422/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3469422</span></a>] [<a href="/pubmed/23071445" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23071445</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.bachmann.2017.320">Bachmann C, Jungbluth H, Muntoni F, Manzur AY, Zorzato F, Treves S. Cellular, biochemical and molecular changes in muscles from patients with X-linked myotubular myopathy due to MTM1 mutations. <span><span class="ref-journal">Hum Mol Genet. </span>2017;<span class="ref-vol">26</span>:320–32.</span> [<a href="/pubmed/28007904" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28007904</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.barth.1998.49">Barth PG, Dubowitz V. X-linked myotubular myopathy--a long-term follow-up study. <span><span class="ref-journal">Eur J Paediatr Neurol. </span>1998;<span class="ref-vol">2</span>:49–56.</span> [<a href="/pubmed/10726846" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10726846</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.bartsch.1999.310">Bartsch O, Kress W, Wagner A, Seemanova E. The novel contiguous gene syndrome of myotubular myopathy (MTM1), male hypogenitalism and Step in Xq28:report of the first familial case. <span><span class="ref-journal">Cytogenet Cell Genet. </span>1999;<span class="ref-vol">85</span>:310–4.</span> [<a href="/pubmed/10449925" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10449925</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.beggs.2018.550">Beggs AH, Byrne BJ, De Chastonay S, Haselkorn T, Hughes I, James ES, Kuntz NL, Simon J, Swanson LC, Yang ML, Yu ZF, Yum SW, Prasad S. A multicenter, retrospective medical record review of X-linked myotubular myopathy: the recensus study. <span><span class="ref-journal">Muscle Nerve. </span>2018;<span class="ref-vol">57</span>:550–60.</span> [<a href="/pmc/articles/PMC5900738/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5900738</span></a>] [<a href="/pubmed/29149770" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29149770</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.bertini.2004.387">Bertini E, Biancalana V, Bolino A, Buj Bello A, Clague M, Guicheney P, Jungbluth H, Kress W, Musaro' A, Nandurkar H, Pirola L, Romero N, Senderek J, Suter U, Sewry C, Tronchere H, Wallgren-Pettersson C, Wishart MJ, Laporte J. 118th ENMC International Workshop on Advances in Myotubular Myopathy. 26-28 September 2003, Naarden, The Netherlands. (5th Workshop of the International Consortium on Myotubular Myopathy). <span><span class="ref-journal">Neuromuscul Disord. </span>2004;<span class="ref-vol">14</span>:387–96.</span> [<a href="/pubmed/15145343" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15145343</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.bevilacqua.2009.283">Bevilacqua JA, Bitoun M, Biancalana V, Oldfors A, Stoltenburg G, Claeys KG, Lac&#x000e8;ne E, Brochier G, Man&#x000e9;r&#x000e9; L, Lafor&#x000ea;t P, Eymard B, Guicheney P, Fardeau M, Romero NB. "Necklace" fibers, a new histological marker of late-onset MTM1-related centronuclear myopathy. <span><span class="ref-journal">Acta Neuropathol. </span>2009;<span class="ref-vol">117</span>:283–91.</span> [<a href="/pubmed/19084976" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19084976</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.biancalana.2003.135">Biancalana V, Caron O, Gallati S, Baas F, Kress W, Novelli G, D'Apice MR, Lagier-Tourenne C, Buj-Bello A, Romero NB, Mandel JL. Characterisation of mutations in 77 patients with X-linked myotubular myopathy, including a family with a very mild phenotype. <span><span class="ref-journal">Hum Genet. </span>2003;<span class="ref-vol">112</span>:135–42.</span> [<a href="/pubmed/12522554" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12522554</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.biancalana.2017.889">Biancalana V, Scheidecker S, Miguet M, Laquerri&#x000e8;re A, Romero NB, Stojkovic T, Abath Neto O, Mercier S, Voermans N, Tanner L, Rogers C, Ollagnon-Roman E, Roper H, Boutte C, Ben-Shachar S, Lornage X, Vasli N, Schaefer E, Laforet P, Pouget J, Moerman A, Pasquier L, Marcorelle P, Magot A, K&#x000fc;sters B, Streichenberger N, Tranchant C, Dondaine N, Schneider R, Gasnier C, Calmels N, Kremer V, Nguyen K, Perrier J, Kamsteeg EJ, Carlier P, Carlier RY, Thompson J, Boland A, Deleuze JF, Fardeau M, Zanoteli E, Eymard B, Laporte J. Affected female carriers of MTM1 mutations display a wide spectrum of clinical and pathological involvement: delineating diagnostic clues. <span><span class="ref-journal">Acta Neuropathol. </span>2017;<span class="ref-vol">134</span>:889–904.</span> [<a href="/pubmed/28685322" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28685322</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.cahill.2007.98">Cahill PJ, Rinella AS, Bielski RJ. Orthopaedic complications of myotubular myopathy. <span><span class="ref-journal">J Pediatr Orthop. </span>2007;<span class="ref-vol">27</span>:98–103.</span> [<a href="/pubmed/17195806" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17195806</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.cao.2007.1052">Cao C, Laporte J, Backer JM, Wandinger-Ness A, Stein MP. Myotubularin lipid phosphatase binds the hVPS15/hVPS34 lipid kinase complex on endosomes. <span><span class="ref-journal">Traffic. </span>2007;<span class="ref-vol">8</span>:1052–67.</span> [<a href="/pubmed/17651088" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17651088</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.chaussade.2003.2448">Chaussade C, Pirola L, Bonnafous S, Blondeau F, Brenz-Verca S, Tronch&#x000e8;re H, Portis F, Rusconi S, Payrastre B, Laporte J, Van Obberghen E. Expression of myotubularin by an adenoviral vector demonstrates its function as a phosphatidylinositol 3-phosphate [PtdIns(3)P] phosphatase in muscle cell lines: involvement of PtdIns(3)P in insulin-stimulated glucose transport. <span><span class="ref-journal">Mol Endocrinol. </span>2003;<span class="ref-vol">17</span>:2448–60.</span> [<a href="/pubmed/14500759" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14500759</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.childers.2014.220ra10">Childers MK, Joubert R, Poulard K, Moal C, Grange RW, Doering JA, Lawlor MW, Rider BE, Jamet T, Dani&#x000e8;le N, Martin S, Rivi&#x000e8;re C, Soker T, Hammer C, Van Wittenberghe L, Lockard M, Guan X, Goddard M, Mitchell E, Barber J, Williams JK, Mack DL, Furth ME, Vignaud A, Masurier C, Mavilio F, Moullier P, Beggs AH, Buj-Bello A. Gene therapy prolongs survival and restores function in murine and canine models of myotubular myopathy. <span><span class="ref-journal">Sci Transl Med. </span>2014;<span class="ref-vol">6</span>:220ra10.</span> [<a href="/pmc/articles/PMC4105197/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4105197</span></a>] [<a href="/pubmed/24452262" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24452262</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.cowling.2014.1350">Cowling BS, Chevremont T, Prokic I, Kretz C, Ferry A, Coirault C, Koutsopoulos O, Laugel V, Romero NB, Laporte J. Reducing dynamin 2 expression rescues X-linked centronuclear myopathy. <span><span class="ref-journal">J Clin Invest. </span>2014;<span class="ref-vol">124</span>:1350–63.</span> [<a href="/pmc/articles/PMC3938268/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3938268</span></a>] [<a href="/pubmed/24569376" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24569376</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.dahl.1995.1108">Dahl N, Hu LJ, Chery M, Fardeau M, Gilgenkrantz S, Nivelon-Chevallier A, Sidaner-Noisette I, Mugneret F, Gouyon JB, Gal A, et al.  Myotubular myopathy in a girl with a deletion at Xq27-q28 and unbalanced X inactivation assigns the MTM1 gene to a 600-kb region. <span><span class="ref-journal">Am J Hum Genet. </span>1995;<span class="ref-vol">56</span>:1108–15.</span> [<a href="/pmc/articles/PMC1801465/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1801465</span></a>] [<a href="/pubmed/7726166" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7726166</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.de_gouyon.1997.1499">de Gouyon BM, Zhao W, Laporte J, Mandel JL, Metzenberg A, Herman GE. Characterization of mutations in the myotubularin gene in twenty six patients with X-linked myotubular myopathy. <span><span class="ref-journal">Hum Mol Genet. </span>1997;<span class="ref-vol">6</span>:1499–504.</span> [<a href="/pubmed/9285787" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9285787</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.dowling.2008.1035">Dowling JJ, Gibbs EM, Feldman EL. Membrane traffic and muscle: lessons from human disease. <span><span class="ref-journal">Traffic. </span>2008;<span class="ref-vol">9</span>:1035–43.</span> [<a href="/pmc/articles/PMC2935664/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2935664</span></a>] [<a href="/pubmed/18266915" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18266915</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.dowling.2012.852">Dowling JJ, Joubert R, Low SE, Durban AN, Messaddeq N, Li X, Dulin-Smith AN, Snyder AD, Marshall ML, Marshall JT, Beggs AH, Buj-Bello A, Pierson CR. Myotubular myopathy and the neuromuscular junction: a novel therapeutic approach from mouse models. <span><span class="ref-journal">Dis Model Mech. </span>2012;<span class="ref-vol">5</span>:852–9.</span> [<a href="/pmc/articles/PMC3484867/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3484867</span></a>] [<a href="/pubmed/22645112" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22645112</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.dowling.2009.e1000372">Dowling JJ, Vreede AP, Low SE, Gibbs EM, Kuwada JY, Bonnemann CG, Feldman EL. Loss of myotubularin function results in T-tubule disorganization in zebrafish and human myotubular myopathy. <span><span class="ref-journal">PLoS Genet. </span>2009;<span class="ref-vol">5</span>:e1000372.</span> [<a href="/pmc/articles/PMC2631153/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2631153</span></a>] [<a href="/pubmed/19197364" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19197364</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.falcone.2014.1455">Falcone S, Roman W, Hnia K, Gache V, Didier N, Lain&#x000e9; J, Aurad&#x000e9; F, Marty I, Nishino I, Charlet-Berguerand N, Romero NB, Marazzi G, Sassoon D, Laporte J, Gomes ER. N-WASP is required for Amphiphysin-2/BIN1-dependent nuclear positioning and triad organization in skeletal muscle and is involved in the pathophysiology of centronuclear myopathy. <span><span class="ref-journal">EMBO Mol Med. </span>2014;<span class="ref-vol">6</span>:1455–75.</span> [<a href="/pmc/articles/PMC4237471/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4237471</span></a>] [<a href="/pubmed/25262827" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25262827</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.felice.2018.339">Felice KJ, Whitaker CH, Wu Q. Whole exome sequencing discloses a pathogenic MTM1 gene mutation and ends the diagnostic odyssey in an older woman with a progressive and seemingly sporadic myopathy: case report and literature review of MTM1 manifesting female carriers. <span><span class="ref-journal">Neuromuscul Disord. </span>2018;<span class="ref-vol">28</span>:339–45.</span> [<a href="/pubmed/29567349" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29567349</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.gavriilidis.2018.198">Gavriilidis C, Laredj L, Solinhac R, Messaddeq N, Viaud J, Laporte J, Sumara I, Hnia K. The MTM1-UBQLN2-HSP complex mediates degradation of misfolded intermediate filaments in skeletal muscle. <span><span class="ref-journal">Nat Cell Biol. </span>2018;<span class="ref-vol">20</span>:198–210.</span> [<a href="/pubmed/29358706" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29358706</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.h_ne.1999.77">H&#x000e4;ne BG, Rogers RC, Schwartz CE. Germline mosaicism in X-linked myotubular myopathy. <span><span class="ref-journal">Clin Genet. </span>1999;<span class="ref-vol">56</span>:77–81.</span> [<a href="/pubmed/10466421" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10466421</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.helliwell.1998.152">Helliwell TR, Ellis IH, Appleton RE. Myotubular myopathy: morphological, immunohistochemical and clinical variation. <span><span class="ref-journal">Neuromuscul Disord. </span>1998;<span class="ref-vol">8</span>:152–61.</span> [<a href="/pubmed/9631395" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9631395</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.hedbergoldfors.2017.843">Hedberg-Oldfors C, Visuttijai K, Topa A, Tulinius M, Oldfors A. Grand paternal inheritance of X-linked myotubular myopathy due to mosaicism, and identification of necklace fibers in an asymptomatic male. <span><span class="ref-journal">Neuromuscul Disord. </span>2017;<span class="ref-vol">27</span>:843–7.</span> [<a href="/pubmed/28622964" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28622964</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.herman.1999.206">Herman GE, Finegold M, Zhao W, de Gouyon B, Metzenberg A. Medical complications in long-term survivors with X-linked myotubular myopathy. <span><span class="ref-journal">J Pediatr. </span>1999;<span class="ref-vol">134</span>:206–14.</span> [<a href="/pubmed/9931531" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9931531</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.herman.2002.114">Herman GE, Kopacz K, Zhao W, Mills PL, Metzenberg A, Das S. Characterization of mutations in fifty North American patients with X-linked myotubular myopathy. <span><span class="ref-journal">Hum Mutat. </span>2002;<span class="ref-vol">19</span>:114–21.</span> [<a href="/pubmed/11793470" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11793470</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.hnia.2011.70">Hnia K, Tronch&#x000e8;re H, Tomczak KK, Amoasii L, Schultz P, Beggs AH, Payrastre B, Mandel JL, Laporte J. Myotubularin controls desmin intermediate filament architecture and mitochondrial dynamics in human and mouse skeletal muscle. <span><span class="ref-journal">J Clin Invest. </span>2011;<span class="ref-vol">121</span>:70–85.</span> [<a href="/pmc/articles/PMC3007152/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3007152</span></a>] [<a href="/pubmed/21135508" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21135508</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.hoffjan.2006.749">Hoffjan S, Thiels C, Vorgerd M, Neuen-Jacob E, Epplen JT, Kress W. Extreme phenotypic variability in a German family with X-linked myotubular myopathy associated with E404K mutation in MTM1. <span><span class="ref-journal">Neuromuscul Disord. </span>2006;<span class="ref-vol">16</span>:749–53.</span> [<a href="/pubmed/17005396" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17005396</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.hu.1996.139">Hu LJ, Laporte J, Kress W, Kioschis P, Siebenhaar R, Poustka A, Fardeau M, Metzenberg A, Janssen EA, Thomas N, Mandel JL, Dahl N. Deletions in Xq28 in two boys with myotubular myopathy and abnormal genital development define a new contiguous gene syndrome in a 430 kb region. <span><span class="ref-journal">Hum Mol Genet. </span>1996;<span class="ref-vol">5</span>:139–43.</span> [<a href="/pubmed/8789451" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8789451</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.jungbluth.2018.151">Jungbluth H, Treves S, Zorzato F, Sarkozy A, Ochala J, Sewry C, Phadke R, Gautel M, Muntoni F. Congenital myopathies: disorders of excitation-contraction coupling and muscle contraction. <span><span class="ref-journal">Nat Rev Neurol. </span>2018;<span class="ref-vol">14</span>:151–67.</span> [<a href="/pubmed/29391587" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29391587</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.ketel.2016.408">Ketel K, Krauss M, Nicot AS, Puchkov D, Wieffer M, M&#x000fc;ller R, Subramanian D, Schultz C, Laporte J, Haucke V. A phosphoinositide conversion mechanism for exit from endosomes. <span><span class="ref-journal">Nature. </span>2016;<span class="ref-vol">529</span>:408–12.</span> [<a href="/pubmed/26760201" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26760201</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.laporte.2000.393">Laporte J, Biancalana V, Tanner SM, Kress W, Schneider V, Wallgren-Pettersson C, Herger F, Buj-Bello A, Blondeau F, Liechti-Gallati S, Mandel JL. MTM1 mutations in X-linked myotubular myopathy. <span><span class="ref-journal">Hum Mutat. </span>2000;<span class="ref-vol">15</span>:393–409.</span> [<a href="/pubmed/10790201" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10790201</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.laporte.2001a.221">Laporte J, Blondeau F, Buj-Bello A, Mandel JL. The myotubularin family: from genetic disease to phosphoinositide metabolism. <span><span class="ref-journal">Trends Genet. </span>2001a;<span class="ref-vol">17</span>:221–8.</span> [<a href="/pubmed/11275328" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11275328</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.laporte.2002.3105">Laporte J, Blondeau F, Gansmuller A, Lutz Y, Vonesch JL, Mandel JL. The PtdIns3P phosphatase myotubularin is a cytoplasmic protein that also localizes to Rac1-inducible plasma membrane ruffles. <span><span class="ref-journal">J Cell Sci. </span>2002;<span class="ref-vol">115</span>:3105–17.</span> [<a href="/pubmed/12118066" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12118066</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.laporte.1998.325">Laporte J, Guiraud-Chaumeil C, Tanner SM, Blondeau F, Hu LJ, Vicaire S, Liechti-Gallati S, Mandel JL. Genomic organization of the MTM1 gene implicated in X-linked myotubular myopathy. <span><span class="ref-journal">Eur J Hum Genet. </span>1998;<span class="ref-vol">6</span>:325–30.</span> [<a href="/pubmed/9781038" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9781038</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.laporte.1997.1505">Laporte J, Guiraud-Chaumeil C, Vincent MC, Mandel JL, Tanner SM, Liechti-Gallati S, Wallgren-Pettersson C, Dahl N, Kress W, Bolhuis PA, Fardeau M, Samson F, Bertini E. Mutations in the MTM1 gene implicated in X-linked myotubular myopathy. ENMC International Consortium on Myotubular Myopathy. European Neuro-Muscular Center. <span><span class="ref-journal">Hum Mol Genet. </span>1997;<span class="ref-vol">6</span>:1505–11.</span> [<a href="/pubmed/9305655" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9305655</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.laporte.1996.175">Laporte J, Hu LJ, Kretz C, Mandel JL, Kioschis P, Coy JF, Klauck SM, Poustka A, Dahl N. A gene mutated in X-linked myotubular myopathy defines a new putative tyrosine phosphatase family conserved in yeast. <span><span class="ref-journal">Nat Genet. </span>1996;<span class="ref-vol">13</span>:175–82.</span> [<a href="/pubmed/8640223" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8640223</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.laporte.2001b.42">Laporte J, Kress W, Mandel JL. Diagnosis of X-linked myotubular myopathy by detection of myotubularin. <span><span class="ref-journal">Ann Neurol. </span>2001b;<span class="ref-vol">50</span>:42–6.</span> [<a href="/pubmed/11456308" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11456308</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.lawlor.2013.1525">Lawlor MW, Armstrong D, Viola MG, Widrick JJ, Meng H, Grange RW, Childers MK, Hsu CP, O'Callaghan M, Pierson CR, Buj-Bello A, Beggs AH. Enzyme replacement therapy rescues weakness and improves muscle pathology in mice with X-linked myotubular myopathy. <span><span class="ref-journal">Hum Mol Genet. </span>2013;<span class="ref-vol">22</span>:1525–38.</span> [<a href="/pmc/articles/PMC3605830/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3605830</span></a>] [<a href="/pubmed/23307925" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23307925</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.lawlor.2016.102">Lawlor MW, Beggs AH, Buj-Bello A, Childers MK, Dowling JJ, James ES, Meng H, Moore SA, Prasad S, Schoser B, Sewry CA. Skeletal Muscle Pathology in X-Linked Myotubular Myopathy: Review With Cross-Species Comparisons. <span><span class="ref-journal">J Neuropathol Exp Neurol. </span>2016;<span class="ref-vol">75</span>:102–10.</span> [<a href="/pmc/articles/PMC4765322/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4765322</span></a>] [<a href="/pubmed/26823526" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26823526</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.lek.2016.285">Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, O'Donnell-Luria AH, Ware JS, Hill AJ, Cummings BB, Tukiainen T, Birnbaum DP, Kosmicki JA, Duncan LE, Estrada K, Zhao F, Zou J, Pierce-Hoffman E, Berghout J, Cooper DN, Deflaux N, DePristo M, Do R, Flannick J, Fromer M, Gauthier L, Goldstein J, Gupta N, Howrigan D, Kiezun A, Kurki MI, Moonshine AL, Natarajan P, Orozco L, Peloso GM, Poplin R, Rivas MA, Ruano-Rubio V, Rose SA, Ruderfer DM, Shakir K, Stenson PD, Stevens C, Thomas BP, Tiao G, Tusie-Luna MT, Weisburd B, Won HH, Yu D, Altshuler DM, Ardissino D, Boehnke M, Danesh J, Donnelly S, Elosua R, Florez JC, Gabriel SB, Getz G, Glatt SJ, Hultman CM, Kathiresan S, Laakso M, McCarroll S, McCarthy MI, McGovern D, McPherson R, Neale BM, Palotie A, Purcell SM, Saleheen D, Scharf JM, Sklar P, Sullivan PF, Tuomilehto J, Tsuang MT, Watkins HC, Wilson JG, Daly MJ, MacArthur DG., Exome Aggregation Consortium.  Analysis of protein-coding genetic variation in 60,706 humans. <span><span class="ref-journal">Nature. </span>2016;<span class="ref-vol">536</span>:285–91.</span> [<a href="/pmc/articles/PMC5018207/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5018207</span></a>] [<a href="/pubmed/27535533" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27535533</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.litman.2018.159">Litman RS, Griggs SM, Dowling JJ, Riazi S. Malignant Hyperthermia Susceptibility and Related Diseases. <span><span class="ref-journal">Anesthesiology. </span>2018;<span class="ref-vol">128</span>:159–67.</span> [<a href="/pubmed/28902673" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28902673</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.mack.2017.839">Mack DL, Poulard K, Goddard MA, Latournerie V, Snyder JM, Grange RW, Elverman MR, Denard J, Veron P, Buscara L, Le Bec C, Hogrel JY, Brezovec AG, Meng H, Yang L, Liu F, O'Callaghan M, Gopal N, Kelly VE, Smith BK, Strande JL, Mavilio F, Beggs AH, Mingozzi F, Lawlor MW, Buj-Bello A, Childers MK. Systemic AAV8-mediated gene therapy drives whole-body correction of myotubular myopathy in dogs. <span><span class="ref-journal">Mol Ther. </span>2017;<span class="ref-vol">25</span>:839–54.</span> [<a href="/pmc/articles/PMC5383631/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5383631</span></a>] [<a href="/pubmed/28237839" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28237839</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.mccrea.2009.483">McCrea HJ, Kretz C, Laporte J, Ment LR. Dementia in a child with myotubular myopathy. <span><span class="ref-journal">Pediatr Neurol. </span>2009;<span class="ref-vol">40</span>:483–5.</span> [<a href="/pmc/articles/PMC3808886/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3808886</span></a>] [<a href="/pubmed/19433289" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19433289</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.motoki.2013.917">Motoki T, Fukuda M, Nakano T, Matsukage S, Fukui A, Akiyoshi S, Hayashi YK, Ishii E, Nishino I. Fatal hepatic hemorrhage by peliosis hepatis in X-linked myotubular myopathy: a case report. <span><span class="ref-journal">Neuromuscul Disord. </span>2013;<span class="ref-vol">23</span>:917–21.</span> [<a href="/pubmed/24011703" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24011703</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.oliveira.2013.540">Oliveira J, Oliveira ME, Kress W, Taipa R, Pires MM, Hilbert P, Baxter P, Santos M, Buermans H, den Dunnen JT, Santos R. Expanding the MTM1 mutational spectrum: novel variants including the first multi-exonic duplication and development of a locus-specific database. <span><span class="ref-journal">Eur J Hum Genet. </span>2013;<span class="ref-vol">21</span>:540–9.</span> [<a href="/pmc/articles/PMC3641378/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3641378</span></a>] [<a href="/pubmed/22968136" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22968136</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.pierson.2007.562">Pierson CR, Agrawal PB, Blasko J, Beggs AH. Myofiber size correlates with MTM1 mutation type and outcome in X-linked myotubular myopathy. <span><span class="ref-journal">Neuromuscul Disord. </span>2007;<span class="ref-vol">17</span>:562–8.</span> [<a href="/pmc/articles/PMC2043149/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2043149</span></a>] [<a href="/pubmed/17537630" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17537630</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.pierson.2005.555">Pierson CR, Tomczak K, Agrawal P, Moghadaszadeh B, Beggs AH. X-linked myotubular and centronuclear myopathies. <span><span class="ref-journal">J Neuropathol Exp Neurol. </span>2005;<span class="ref-vol">64</span>:555–64.</span> [<a href="/pubmed/16042307" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16042307</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.raess.2017.49">Raess MA, Friant S, Cowling BS, Laporte J. WANTED - Dead or alive: Myotubularins, a large disease-associated protein family. <span><span class="ref-journal">Adv Biol Regul. </span>2017;<span class="ref-vol">63</span>:49–58.</span> [<a href="/pubmed/27666502" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27666502</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.robb.2011.379">Robb SA, Sewry CA, Dowling JJ, Feng L, Cullup T, Lillis S, Abbs S, Lees MM, Laporte J, Manzur AY, Knight RK, Mills KR, Pike MG, Kress W, Beeson D, Jungbluth H, Pitt MC, Muntoni F. Impaired neuromuscular transmission and response to acetylcholinesterase inhibitors in centronuclear myopathies. <span><span class="ref-journal">Neuromuscul Disord. </span>2011;<span class="ref-vol">21</span>:379–86.</span> [<a href="/pubmed/21440438" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21440438</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.robinson.2006.403">Robinson FL, Dixon JE. Myotubularin phosphatases: policing 3-phosphoinositides. <span><span class="ref-journal">Trends Cell Biol. </span>2006;<span class="ref-vol">16</span>:403–12.</span> [<a href="/pubmed/16828287" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16828287</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.roman.2017.1189">Roman W, Martins JP, Carvalho FA, Voituriez R, Abella JVG, Santos NC, Cadot B, Way M, Gomes ER. Myofibril contraction and crosslinking drive nuclear movement to the periphery of skeletal muscle. <span><span class="ref-journal">Nat Cell Biol. </span>2017;<span class="ref-vol">19</span>:1189–201.</span> [<a href="/pmc/articles/PMC5675053/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5675053</span></a>] [<a href="/pubmed/28892082" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28892082</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.romero.2010.223">Romero NB. Centronuclear myopathies: a widening concept. <span><span class="ref-journal">Neuromuscul Disord. </span>2010;<span class="ref-vol">20</span>:223–8.</span> [<a href="/pubmed/20181480" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20181480</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.sabha.2016.3613">Sabha N, Volpatti JR, Gonorazky H, Reifler A, Davidson AE, Li X, Eltayeb NM, Dall'Armi C, Di Paolo G, Brooks SV, Buj-Bello A, Feldman EL, Dowling JJ. PIK3C2B inhibition improves function and prolongs survival in myotubular myopathy animal models. <span><span class="ref-journal">J Clin Invest. </span>2016;<span class="ref-vol">126</span>:3613–25.</span> [<a href="/pmc/articles/PMC5004942/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5004942</span></a>] [<a href="/pubmed/27548528" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27548528</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.sarnat.1990.109">Sarnat HB. Myotubular myopathy: arrest of morphogenesis of myofibres associated with persistence of fetal vimentin and desmin. Four cases compared with fetal and neonatal muscle. <span><span class="ref-journal">Can J Neurol Sci. </span>1990;<span class="ref-vol">17</span>:109–23.</span> [<a href="/pubmed/2357647" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2357647</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.savarese.2016.292">Savarese M, Musumeci O, Giugliano T, Rubegni A, Fiorillo C, Fattori F, Torella A, Battini R, Rodolico C, Pugliese A, Piluso G, Maggi L, D'Amico A, Bruno C, Bertini E, Santorelli FM, Mora M, Toscano A, Minetti C, Nigro V. Novel findings associated with MTM1 suggest a higher number of female symptomatic carriers. <span><span class="ref-journal">Neuromuscul Disord. </span>2016;<span class="ref-vol">26</span>:292–9.</span> [<a href="/pmc/articles/PMC4862961/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4862961</span></a>] [<a href="/pubmed/27017278" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27017278</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.sewry.1998.394">Sewry CA. The role of immunocytochemistry in congenital myopathies. <span><span class="ref-journal">Neuromuscul Disord. </span>1998;<span class="ref-vol">8</span>:394–400.</span> [<a href="/pubmed/9713857" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9713857</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.tasfaout.2017.15661">Tasfaout H, Buono S, Guo S, Kretz C, Messaddeq N, Booten S, Greenlee S, Monia BP, Cowling BS, Laporte J. Antisense oligonucleotide-mediated Dnm2 knockdown prevents and reverts myotubular myopathy in mice. <span><span class="ref-journal">Nat Commun. </span>2017;<span class="ref-vol">8</span>:15661.</span> [<a href="/pmc/articles/PMC5467247/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5467247</span></a>] [<a href="/pubmed/28589938" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28589938</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.taylor.2000.8910">Taylor GS, Maehama T, Dixon JE. Inaugural article: myotubularin, a protein tyrosine phosphatase mutated in myotubular myopathy, dephosphorylates the lipid second messenger, phosphatidylinositol 3-phosphate. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2000;<span class="ref-vol">97</span>:8910–5.</span> [<a href="/pmc/articles/PMC16795/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC16795</span></a>] [<a href="/pubmed/10900271" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10900271</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.tosch.2010.375">Tosch V, Vasli N, Kretz C, Nicot AS, Gasnier C, Dondaine N, Oriot D, Barth M, Puissant H, Romero NB, Bonnemann CG, Heller B, Duval G, Biancalana V, Laporte J. Novel molecular diagnostic approaches for X-linked centronuclear (myotubular) myopathy reveal intronic mutations. <span><span class="ref-journal">Neuromuscul Disord. </span>2010;<span class="ref-vol">20</span>:375–81.</span> [<a href="/pubmed/20434914" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20434914</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.toussaint.2011.253">Toussaint A, Cowling BS, Hnia K, Mohr M, Oldfors A, Schwab Y, Yis U, Maisonobe T, Stojkovic T, Wallgren-Pettersson C, Laugel V, Echaniz-Laguna A, Mandel J-L, Nishino I, Laporte J. Defects in amphiphysin 2 (Bin1) and triads in several forms of centronuclear myopathies. <span><span class="ref-journal">Acta Neuropathol. </span>2011;<span class="ref-vol">121</span>:253–66.</span> [<a href="/pubmed/20927630" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20927630</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.tsai.2005.245">Tsai TC, Horinouchi H, Noguchi S, Minami N, Murayama K, Hayashi YK, Nonaka I, Nishino I. Characterization of MTM1 mutations in 31 Japanese families with myotubular myopathy, including a patient carrying 240 kb deletion in Xq28 without male hypogenitalism. <span><span class="ref-journal">Neuromuscul Disord. </span>2005;<span class="ref-vol">15</span>:245–52.</span> [<a href="/pubmed/15725586" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15725586</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.tsujita.2004.13817">Tsujita K, Itoh T, Ijuin T, Yamamoto A, Shisheva A, Laporte J, Takenawa T. Myotubularin regulates the function of the late endosome through the gram domain-phosphatidylinositol 3,5-bisphosphate interaction. <span><span class="ref-journal">J Biol Chem. </span>2004;<span class="ref-vol">279</span>:13817–24.</span> [<a href="/pubmed/14722070" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14722070</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.vincent.1998.241">Vincent MC, Guiraud-Chaumeil C, Laporte J, Manouvrier-Hanu S, Mandel JL. Extensive germinal mosaicism in a family with X-linked myotubular myopathy simulates genetic heterogeneity. <span><span class="ref-journal">J Med Genet. </span>1998;<span class="ref-vol">35</span>:241–3.</span> [<a href="/pmc/articles/PMC1051250/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1051250</span></a>] [<a href="/pubmed/9541111" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9541111</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.wang.2012.363">Wang CH, Dowling JJ, North K, Schroth MK, Sejersen T, Shapiro F, Bellini J, Weiss H, Guillet M, Amburgey K, Apkon S, Bertini E, Bonnemann C, Clarke N, Connolly AM, Estournet-Mathiaud B, Fitzgerald D, Florence JM, Gee R, Gurgel-Giannetti J, Glanzman AM, Hofmeister B, Jungbluth H, Koumbourlis AC, Laing NG, Main M, Morrison LA, Munns C, Rose K, Schuler PM, Sewry C, Storhaug K, Vainzof M, Yuan N. Consensus statement on standard of care for congenital myopathies. <span><span class="ref-journal">J Child Neurol. </span>2012;<span class="ref-vol">27</span>:363–82.</span> [<a href="/pmc/articles/PMC5234865/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5234865</span></a>] [<a href="/pubmed/22431881" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22431881</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.wilmshurst.2010.717">Wilmshurst JM, Lillis S, Zhou H, Pillay K, Henderson H, Kress W, M&#x000fc;ller CR, Ndondo A, Cloke V, Cullup T, Bertini E, Boennemann C, Straub V, Quinlivan R, Dowling JJ, Al-Sarraj S, Treves S, Abbs S, Manzur AY, Sewry CA, Muntoni F, Jungbluth H. RYR1 mutations are a common cause of congenital myopathies with central nuclei. <span><span class="ref-journal">Ann Neurol. </span>2010;<span class="ref-vol">68</span>:717–26.</span> [<a href="/pubmed/20839240" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20839240</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mtm.REF.yu.2003.148">Yu S, Manson J, White S, Bourne A, Waddy H, Davis M, Haan E. X-linked myotubular myopathy in a family with three adult survivors. <span><span class="ref-journal">Clin Genet. </span>2003;<span class="ref-vol">64</span>:148–52.</span> [<a href="/pubmed/12859411" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12859411</span></a>]</div></li></ul></div></div><div id="mtm.Chapter_Notes"><h2 id="_mtm_Chapter_Notes_">Chapter Notes</h2><p><b>Author History</b></p><p>Soma Das, PhD (2002-present)<br />James J Dowling, MD, PhD (2011-present)<br />Gail Ellen Herman, MD, PhD; Nationwide Children's Hospital, Columbus (2002-2011)<br />Michael W Lawlor, MD, PhD (2018-present)<br />Christopher R Pierson, MD, PhD; Nationwide Children's Hospital, Columbus (2011-2018)</p><div id="mtm.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>23 August 2018 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>6 October 2011 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>5 October 2006 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>3 May 2004 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>25 February 2002 (me) Review posted live</div></li><li class="half_rhythm"><div>2 October 2001 (gh) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1432</span><span class="label">PMID: <a href="/pubmed/20301605" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301605</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/retinoschisis/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/opitz/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1432&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1432/?report=reader">PubReader</a></li><li><a href="/books/NBK1432/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1432" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1432" style="display:none" title="Cite this Page"><div class="bk_tt">Dowling JJ, Lawlor MW, Das S. X-Linked Myotubular Myopathy. 2002 Feb 25 [Updated 2018 Aug 23]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1432/pdf/Bookshelf_NBK1432.pdf">PDF version of this page</a> (290K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#mtm.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#mtm.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#mtm.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#mtm.Genetically_Related_Allelic_Disorder" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#mtm.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#mtm.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#mtm.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#mtm.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#mtm.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#mtm.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#mtm.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=4534[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">MTM1</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1480812" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1480812" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1480812" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1480812" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301298" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Dystrophinopathies</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Dystrophinopathies<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Darras BT, Urion DK, Ghosh PS. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24006547" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ornithine Transcarbamylase Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ornithine Transcarbamylase Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Lichter-Konecki U, Caldovic L, Morizono H, Simpson K. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28685322" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Affected female carriers of MTM1 mutations display a wide spectrum of clinical and pathological involvement: delineating diagnostic clues.</a><span class="source">[Acta Neuropathol. 2017]</span><div class="brieflinkpop offscreen_noflow">Affected female carriers of MTM1 mutations display a wide spectrum of clinical and pathological involvement: delineating diagnostic clues.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Biancalana V, Scheidecker S, Miguet M, Laquerrière A, Romero NB, Stojkovic T, Abath Neto O, Mercier S, Voermans N, Tanner L, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Acta Neuropathol. 2017 Dec; 134(6):889-904. Epub 2017 Jul 6.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301567" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> X-Linked Otopalatodigital Spectrum Disorders</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> X-Linked Otopalatodigital Spectrum Disorders<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Robertson S. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24278995" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">CASK</i>-Related Disorders</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">CASK</i>-Related Disorders<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Moog U, Uyanik G, Kutsche K. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301605" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301605" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e0419b3dd21425a255b1f6f">X-Linked Myotubular Myopathy - GeneReviews®</a><div class="ralinkpop offscreen_noflow">X-Linked Myotubular Myopathy - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:23:47-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal103&amp;ncbi_phid=CE8A40B7E04091C100000000070002B0&amp;ncbi_session=CE8A40B7E0419B21_1792SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1432%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1432&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1432/&amp;ncbi_pagename=X-Linked Myotubular Myopathy - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8A40B7E0419B21_1792SID /projects/books/PBooks@5.22 portal103 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>